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Retinal blood vessels are surrounded by Müller cells’ endfeet, forming a link through 
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Ƣ and fibroblast growth factors (FGFs) (184,18
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(199,244). In the model, the RPE and Bruch’s membrane are subjected to targeted 
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per eye were made by laser photocoagulation (680 nm; 100 Ƭm spot diameter; 100 
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Ƣ family members is complex; TGF
Ƣ2 induces furin expression, and 
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Ƣ activity (381). However, 
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Ƣ1 and 
Ƣ2 was addressed, it was determined that even 
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Ƣ have been described. In the OIR model, intraperitoneally injected 
D<J<E:?PD8CJK<D:<CC@EM8;<;KFK?<I<K@E88E;J<:I<K<;/"!
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Ƣ inhibition might be a novel therapeutic target for 
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Ƣ remains unclear in the OIR model and ischemic eye 
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Ƣ1 (Study III). In 
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PURPOSE. The role of R-Ras in retinal angiogenesis and vascular permeability was evaluated in
an oxygen-induced retinopathy (OIR) model using R-Ras knockout (KO) mice and in human
diabetic neovascular membranes.
METHODS. Mice deﬁcient for R-Ras and their wild-type (WT) littermates were subjected to 75%
oxygen from postnatal day 7 (P7) to P12 and then returned to room air. At P17 retinal
vascularization was examined from whole mounts, and retinal vascular permeability was
studied using Miles assay. Real-time RT-PCR, Western blotting, and immunohistochemistry
were used to assess the expression of R-Ras in retina during development or in the OIR
model. The degree of pericyte coverage and vascular endothelial (VE)-cadherin expression on
WT and R-Ras KO retinal blood vessels was quantiﬁed using confocal microscopy. The
correlation of R-Ras with vascular endothelial growth factor receptor 2 (VEGFR2) and human
serum albumin on human proliferative diabetic retinopathy membranes was assessed using
immunohistochemistry.
RESULTS. In retina, R-Ras expression was mostly restricted to the vasculature. Retinal vessels in
the R-Ras KO mice were signiﬁcantly more permeable than WT controls in the OIR model. A
signiﬁcant reduction in the direct physical contact between pericytes and blood vessel
endothelium as well as reduced VE-cadherin immunostaining was found in R-Ras–deﬁcient
mice. In human proliferative diabetic retinopathy neovascular membranes, R-Ras expression
negatively correlated with increased vascular leakage and expression of VEGFR2, a marker of
blood vessel immaturity.
CONCLUSIONS. Our results suggest that R-Ras has a role in controlling retinal vessel maturation
and stabilization in ischemic retinopathy and provides a potential target for pharmacologic
manipulation to treat diabetic retinopathy.
Keywords: retina, diabetic retinopathy, neovascularization, retinal ischemia
Diabetic macular edema (DME) and proliferative diabeticretinopathy (PDR) are the two forms of diabetic retinop-
athy causing blindness. Vascular endothelial growth factor
(VEGF) plays a crucial role in these diseases by causing vascular
leakage and pathologic neovascularization.1–3 Anti-VEGF drugs
are regarded as the mainstay of treatment for patients affected
by DME. However, VEGF inhibition fails to provide sufﬁcient
efﬁcacy in all DME cases; only half of patients attain signiﬁcant
improvement in visual acuity.4 Anti-VEGF therapy is also
accompanied by rare, but severe, ocular and systemic side
effects. In PDR, anti-VEGF may be associated with development
of tractional retinal detachment5,6 Furthermore, intravitreally
administered anti-VEGF agents may cause sustained systemic
VEGF inhibition7,8 This is why they are relatively contraindi-
cated in pregnant women9 and patients with cardiovascular
insufﬁciency.10,11 Thus, alternative therapies are needed for
more effective and safer treatment of diabetic retinopathy.12,13
R-Ras is a small GTPase of the Ras family of oncogenes.14
Despite the close structural similarity to other members of the
Ras family, the function of R-Ras is distinct from other Ras
proteins.15 Whereas all other members of the Ras family may
cause malignant transformation, R-Ras has very little or no
transforming activity.16 Furthermore, the opposing functions of
R-Ras and H-Ras extend to cell–extracellular matrix (ECM)
adhesion,17 cell differentiation,18 and signaling.19 These oppos-
ing functions have led to the suggestion that the balance
between R-Ras and other Ras members acts as a switch that
controls proliferation and invasion versus quiescence in
cells.15,20,21
Recently, active Ras signaling has been implicated as a key
driver of pathologic angiogenesis in neovascular diseases of the
iovs.arvojournals.org j ISSN: 1552-5783 4898
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retina.22 Conversely, exactly the opposite role has recently
been shown for R-Ras in the regulation of angiogenesis.20 R-Ras
function has been shown to be essential for the establishment
of mature and functional blood vessels in tumors by
stabilization of immature, leaky vessels, enhancing perfusion
and ultimately reducing plasma leakage.15,21 Based on these
functions, R-Ras has been classiﬁed as an antiangiogenic
molecule. However, R-Ras is functionally different from classic
antiangiogenic agents as it does not induce endothelial cell
apoptosis as do other antiangiogenic molecules, but actually
promotes endothelial cell survival.20 Thus, R-Ras could provide
a potential agonistic therapeutic target for treatment of a
variety of retinal diseases associated with ischemia, neovascu-
larization, and vascular leakage. In the present study, the role of
R-Ras in the retina was studied by analyzing expression of R-Ras
in the retina and by analyzing the effect of R-Ras deﬁciency on
the structural and functional integrity of retinal vasculature
during development and ischemic retinopathy using an
oxygen-induced retinopathy model (OIR). To address the role
of R-Ras in PDR, association of its expression with vascular




For the experiments, wild-type (WT) C57BL/6 mice from
Harlan Sprague Dawley (Indianapolis, IN, USA) and homozy-
gous R-Ras knockout (KO) mice were used. R-Ras KO mice
with an insertion deleting R-Ras expression between exons 4
and 5 of Rras on chromosome 7 (R-Ras KO mice) have been
described previously.20 Before any experiments, R-Ras hetero-
zygous mice were backcrossed eight times with the C57BL/6
strain to obtain homozygous KO and WT mice in the same
genetic background. The mice were bred, and the genotype
was determined by PCR. Mice were fed with standard
laboratory pellets and water ad libitum. All animal experiments
were performed according to the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research in accordance
with protocols approved by the National Animal Ethics
Committee of Finland.
Oxygen-Induced Retinopathy Model
The experiments on the OIR model were carried out as
described in detail previously.23,24 Brieﬂy, neonatal mice at
postnatal day 7 (P7) were exposed to 75% oxygen for 5 days. At
P12, they were returned to normal room air.23 Animals were
euthanized at P12 to assess the degree of vascular regression
and at P17 to determine the rate of retinal revascularization
and preretinal neovascularization. As postnatal weight gain has
been shown to affect outcome in the OIR model,25 only the
pups weighing between 6.3 and 7.5 g at P17 were included in
the study.
Immunohistochemistry (IHC) and Isolectin GS-IB4
Staining
For the analysis of retinal vasculature, eyes were enucleated,
ﬁxed with 4% paraformaldehyde (PFA), and retinas dissected.
Flat-mount retinas were blocked in 20% normal goat and 20%
fetal bovine serums for 2 hours, incubated overnight Isolectin
(Isolectin GS-IB4, 1:200; Invitrogen, Carlsbad, CA, USA) and
with anti-NG2 chondroitin sulfate proteoglycan antibody (1:80;
Millipore, Billerica, MA), followed by Alexa Fluor-conjugated
secondary antibody. Retinas were imaged via confocal micro-
scope (LSM 700; Carl Zeiss, Oberkochen, Germany) and the
rate of angiogenesis was determined during development (P0–
P6) and in the OIR model as previously described.24 Brieﬂy,
retinas were imaged using confocal microscopy (Carl Zeiss LSM
700) with 53 objective. By focusing just above the inner
limiting membrane of the retina, the preretinal neovascular
tufts were readily distinguished from the underlying superﬁcial
vascular plexus. Areas of vascular obliteration and pathologic
neovascularization (meaning neovascular tufts) were quanti-
ﬁed from these images using image editing software (Adobe
Photoshop CS3; Adobe Systems, Inc., San Jose, CA, USA). The
rate of developmental angiogenesis at P0 to P6 was determined
by measuring the length of vasculature from the optic nerve to
the tips of the blood vessels. Four measurements per retina
were taken and an average was calculated.
For immunohistochemistry, the eyes were ﬁxed with 4%
PFA and embedded in parafﬁn or immediately frozen in
ornithine carbamoyltransferase embedding compound in iso-
pentane cooled with liquid nitrogen and later ﬁxed with
acetone. The IHC was carried out on 4- to 6-lm-thick tissue
sections using the following primary antibodies: rabbit anti–R-
Ras (1:50) and rabbit anti-VEGFR2 (1:100; both Cell Signaling
Technology, Danvers, MA, USA), rabbit anti–R-Ras (1:750) and
mouse anti-VEGFR2 (1:200, clone sc.6251; both Santa Cruz
Biotechnology, Dallas, TX, USA), rat anti-mouse CD31 (1:50;
BD Pharmingen, San Diego, CA, USA), guinea pig anti-NG2
antibody (1:100, gift from William Stallcup),26 rabbit anti-
Syndecan (1:500) and rabbit anti-human vascular endothelial
(VE)-cadherin (1:500; both from Abcam, Cambridge, UK), and
rabbit anti-human serum albumin (1:100; Lifespan Biosciences,
Seattle, WA, USA), followed by horseradish peroxidase (HRP)
or ﬂuorescein-conjugated secondary antibodies. Hematoxylin
staining was used as a counterstain. Samples were mounted
with Vectashield mounting medium with 40,6-diamidino-2-
phenylindole (Vector Laboratories) and analyzed via confocal
microscope. Each staining experiment included sections
stained without primary antibody as negative controls.
Percentage of R-Ras positive cells in preretinal neovessels
were quantiﬁed manually by using the count tool in Adobe
Photoshop (Adobe Systems, Inc.) (n ¼ 6 mice, 4–6 sections/
retina).
Quantiﬁcation of Pericyte Coverage and VE-
Cadherin Colocalization With CD31
Pericyte coverage of the blood vessels was quantiﬁed from WT
and R-Ras KO P17 OIR model whole-mount retinas. Samples
were imaged using confocal microscopy (Carl Zeiss LSM 700)
with a 633 objective lens, and 3D pictures were made from Z-
stacks. Pictures selected for the analysis were randomly taken
from Isolectin IB4 and NG2-stained ﬂat-mounts from the most
superﬁcial vascular plexus at the tips of the blood vessels next
to avascular area. This is a region of retina where the blood
vessels are growing toward the optic nerve. Direct contact
between pericytes (NG2) and endothelial cells (Isolectin B4)
were quantiﬁed by colocalization analysis with BioImageXD
(provided in the public domain at http://www.bioimagexd.
org).27 The percentage of EC area colocalized with pericyte
area was quantiﬁed in each image, and the result expressed as a
mean of two different images for each retina. The intensity of
VE-cadherin staining and colocalization of VE-cadherin and
CD31 was quantiﬁed from frozen sections using BioImage XD.
Real-Time Quantitative PCR (qPCR)
Eyes were collected at P0, P4, P7, P12, P17, and P22 and
placed immediately in cold RNA stabilization reagent (RNA-
later; Sigma-Aldrich Corp., St. Louis, MO, USA) for the
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duration of dissection of the retinas. RNAwas extracted using
RNA isolation kit (RNeasy Mini Kit; Qiagen, Hilden, Germany)
following the manufacturer’s instructions. The integrity of
extracted RNA was veriﬁed on formaldehyde agarose gel.
Reverse transcription of RNA was carried out using cDNA
synthesis kit (Maxima First Strand cDNA Synthesis Kit;
Thermo Fisher Scientiﬁc, Boston, MA, USA), according to
the manufacturer’s instructions. Real-time qPCR was done
using the PCR dye (SYBR Green; Thermo Fisher Scientiﬁc)
method according to the manufacturer’s recommendations
and performed in white 96-well plates (Multiply PCR plates;
Sarstedt, Nu¨mbrecht, Germany). The ﬂuorescence signal was
detected using a sequence detection system (ABI Prism 7000
Sequence Detection System 1.2; Applied Biosystems, Carls-
bad, CA, USA). The following intron-spanning primers
speciﬁc for exon 3 and 4 of Rras were used: 5 0-ACAGGCA
GAGTTTCAATGAG-3 0 (forward), 5 0-GTTCTCCAGATCTGCC
TTG-30 (reverse). Ppia was used as an endogenous control
gene (5 0-CACCGTGTTCTTCGACATC-3 0 and 5 0-ATTCTGTGA
AAGGAGGAACC-30), allowing the comparison of samples.20
Two or three replicates were analyzed for each sample, and
the results were expressed as a mean for each sample.
Negative, no template (NTC) and no reverse transcriptase (no
RT), controls were included in every qPCR analysis. A melting
curve analysis was performed to check for unspeciﬁc PCR
products (which didn’t occur). Reaction efﬁciencies for both
primer pairs were tested with standard curve analysis in
different time points. Due to similar efﬁciencies for both
primer pairs, the differences in gene expression levels were
determined by the comparative Ct method (DDCt method).28
Vascular Permeability Assay
Vascular permeability was quantiﬁed by Miles assay in retinas
as described previously.29 Brieﬂy, the mice were injected with
2% Evans Blue ([EB], 150 lL/20g; Sigma-Aldrich Corp.)
intraperitoneally, and the circulation time was 24 h for P16
or 1 hour for P17 injected mice. Phosphate-buffered saline–
injected mice were used as a negative control. Animals were
euthanized at P17, and blood was collected from the left
ventricle. Retinas were dissected and weighed. Blood was
centrifuged at 3,550g for 15 minutes, and plasma was diluted
1:100 and 1:1000 in N, N-dimethylformamide (Sigma-Aldrich
Corp.). All samples were incubated in a shaker (100 rpm) in
200 lL N, N-dimethylformamide overnight at 788C. Retinas
were centrifuged at 17,000g for 45 minutes at 48C, and the
supernatants were collected. The EB absorbance of each
sample was measured at 620 nm by spectrophotometer. EB
concentration in the retina was proportioned and normalized
by the weight of the retina and the amount of EB concentration
in the plasma.30
Western Blotting
Retinas were lysed in 10 lL of cold RIPA buffer per 1 mg of
tissue with added protease inhibitor (cOmplete; Roche, Basel,
Switzerland) and phosphatase inhibitor (Halt; Thermo Fisher
Scientiﬁc).
The tissues were homogenized using CK14 beads and a
tissue homogenizer (Precellys; Bertin Technologies, Montigny le-
Bretonneux, France). From each sample, 40 lg of protein was
loaded per well of a 4-12% gradient gel (NuPAGE; Invitrogen,
Carlsbad, CA, USA) and electroblotted on polyvinylidene
ﬂuoride membranes (Immun-Blo; Bio-Rad Laboratories, Hercu-
les, California). For detection of speciﬁc proteins by immuno-
blotting, the following primary antibodies were used: rabbit
anti–R-Ras (1:500; Cell Signaling Technology), goat anti-GAPDH
(1:500: AbCam) and horse anti-mouse IgG (1:2000; Cell
Signaling Technology). Primary antibodies were detected by
HRP-coupled antibodies. Western blot images were captured via
software (ImageQuant; GE Healthcare, Chalfont St. Giles, UK)
and quantiﬁed by densitometry using Adobe Photoshop CS3
software, where GAPDH was used to normalize for protein
loading. A calibrator control sample was included in every
membrane to enable sample comparison between different
membranes.
Retinal and Neovascular Samples From Human
Patients
Preretinal neovascular membranes were obtained from eight
type I diabetic patients who were undergoing pars plana
vitrectomy for the treatment of PDR. All patients were
Caucasians, and altogether there were ﬁve females and three
males. At the time of pars plana, vitrectomy patients’ mean
age was 33 years (range, 27–56 years) and mean duration of
diabetes was 24 years (range, 16–32 years). Normal human
retinas were obtained from patients whose eyes were
enucleated due to choroidal melanoma. The protocol for
collecting human tissue samples was approved by the
institutional review boards of the Pirkanmaa Hospital
District and the Kuopio University Hospital. The study was
conducted in accordance with the Declaration of Helsinki.
All patients gave written informed consent. During vitrecto-
my, the ﬁbrovascular membranes were isolated, grasped
with vitreous forceps, and pulled out through a sclerotomy.
The sample was immediately ﬁxed with 4% formaldehyde for
3 h, transferred to 70% ethanol, embedded in parafﬁn, and
processed for immunohistochemistry. The number of R-Ras–
positive neovessels was calculated from CD31 and R-Ras–
double-stained tissue sections, and correlation between R-
Ras and VEGFR2 was quantiﬁed from R-Ras and VEGFR2
double-stained sections. Immunohistochemistry against hu-
man serum albumin (HSA) was done to quantify the amount
of vascular leakage outside the neovessels. Quantiﬁcation
was done using IHC Proﬁler plugin in ImageJ software
(http://imagej.nih.gov/ij/; provided in the public domain by
National Institutes of Health, Bethesda, MD, USA). The area
of positive staining for HSA was compared to the total
analyzed area, and correlation analysis between HSA and
percentage of R-Ras–positive neovessels was performed for
each sample.
Statistical Analysis
Student’s t-test was conducted for normally distributed data
and nonparametric Mann-Whitney U test using statistical
software (GraphPad Prism 6.01; GraphPad Software, San
Diego, CA, USA, and IBM SPSS Statistics; IBM, Amonk, NY,
USA) for nonnormally distributed data to test the statistical
signiﬁcance of the results. Spearman’s rank correlation test was
conducted to test correlation between two variables. P values
less than 0.05 were considered statistically signiﬁcant.
RESULTS
R-Ras Expression Peaks During Retinal
Developmental Angiogenesis But Does Not
Inﬂuence the Rate of Developmental Angiogenesis
R-Ras KO mice are fertile and show no obvious morphologic
abnormalities,20,31 and their eyes appear normal upon histo-
logic examination. To address the role of R-Ras on retinal
angiogenesis in vivo, the expression proﬁle of R-Ras in the
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developing mouse retina as well as the developmental rate of
angiogenesis in WT and R-Ras KO mice were characterized.
To assess the temporal expression pattern of R-Ras during
developmental retinal angiogenesis, qPCR and Western blot
analysis were used. Quantitative PCR demonstrated that the
Rras mRNA expression increased from P0 onward, peaked at
P17, and started to decline from P17 until P22. Western blot
analysis demonstrated a R-Ras protein expression proﬁle
similar to the mRNA proﬁle: an increase in expression from
P0 until P17 and a decline from P17 to P22 (Supplementary
Fig. S1). The increase in Rras mRNA and protein levels from
P0 to P17 correlates with the development of retinal
vascular plexuses.32 The R-Ras levels peaked at P17, when
all three vascular plexuses are formed and vascular density
peaks in the retina33 (Supplementary Fig. S1). The ﬁndings
are consistent with the notion that R-Ras appears in the
blood vessels during their differentiation and is most
strongly expressed in fully differentiated, quiescent blood
vessels.20 The reduction in Rras mRNA and protein
expression levels from P17 to P22 can be explained by the
remodeling of retinal vasculature (including vascular prun-
ing), the outcome of which is decreased endothelial cell
density at P28.34 Consistent with this ﬁnding, the results
show a similar decrease in the intensity of Isolectin IB4
staining from P12 onward (Supplementary Fig. S2). No R-Ras
protein or mRNA expression was detected in the retinas
collected from R-Ras KO mice.
To explore whether the increase in R-Ras expression level
seen during retinal development inﬂuences the rate of
superﬁcial vascular plexus formation (developmental angio-
genesis), retinas from P0, P2, P4, and P6 WT and R-Ras KO
mice were analyzed. In P0, P2, P4, and P6 neonatal mice, the
diameter of retinal superﬁcial vascular plexuses were similar
both in R-Ras KO and WT mice, indicating that R-Ras
expression is not necessary for in vivo angiogenesis during
neonatal development (Supplementary Fig. S3). The lack of
FIGURE 1. Hypoxia-driven R-Ras expression in the OIR model. Hypoxia-induced angiogenesis in retina was studied with the OIR model. Retinas
were harvested immediately after the exposure to hyperoxia (P12) and after hypoxia-driven pathologic angiogenesis has reached its maximum at
P17. Retinas from normal mice were harvested at corresponding time points. Retinas were subjected to either quantitative mRNA (real-time qPCR)
analysis using SYBR Green method or protein (Western blotting) analysis. For immunoblotting, retinal protein supernatants were electrophoresed
on gradient gels, standard Western blotting was carried out with R-Ras–speciﬁc antibody, and GAPDH detection was used as a loading control. (A)
The graph represents fold changes (2DDCt method) in the RrasmRNA expression level relative to the RrasmRNA expression level of normal mice at
P12. The level of Rras mRNA expression between normal and OIR model retinas is equal at P12, whereas at P17 hypoxia leads to 2.5-fold
upregulation of Rras mRNA (P ¼ 0.016, * nonparametric Mann-Whitney U test). Error bars represent the minimum and maximum of the fold
change. (P12, P17 OIR: n ¼ 4; P17, P12 OIR: n ¼ 5.) (B, C) The level of R-Ras protein expression was quantiﬁed by densitometric analysis of
immunoblotted protein. R-Ras protein level at P17 shows a 7.5-fold increase (P¼ 0.016) during hypoxia-induced angiogenesis. Error bars represent
6 95% conﬁdence intervals. (P12: n¼6; P12 OIR: n¼7; P17: n¼5; P17: n¼5.) The results are analyzed with nonparametric Mann-Whitney U test.
The samples presented above were run on the same gel. Representative samples were cropped and presented side-by-side.
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inﬂuence on development of retinal vasculature by R-Ras is in
line with the above-reported low expression of R-Ras at the
early stages of retinal vascular development (Supplementary
Fig. S1).
Induction and Selective Disappearance of R-Ras
From the Pathologic Neovasculature in OIR
Next, the R-Ras expression proﬁle in the OIR model was
analyzed using WT mice. Using qPCR, a 2.5-fold increase of
Rras mRNA from normal P17 to P17 OIR model retinas was
detected. Using Western blot analysis, a 7.5-fold increase in R-
Ras protein levels was seen in OIR P17 retinas compared to
healthy P17 retinas. At P12, the expression of R-Ras was
reduced in OIR. The amount of R-Ras expression is in line with
regression of the vasculature at P12 and vessel regrowth at P17
in the OIR model (Fig. 1). Using R-Ras immunohistochemistry,
R-Ras was found to be localized mainly to the blood vessels in
OIR retinas (Fig. 2, Supplementary Fig. S4). A faint R-Ras
expression was also detected outside of the retinal blood
vessels in mouse retina (Fig. 2A). This immunohistochemical
signal most probably represents low expressions from retinal
neuronal cells, which are known to express R-Ras.35 Using R-
Ras and endothelial cell (CD31), as well as R-Ras and pericyte
(NG2), double-staining, R-Ras expression was shown to be
conﬁned to endothelial cells and pericytes in retinal vessels
(Fig. 2). It appeared that all of the retinal blood vessels
expressed R-Ras, whereas only 68% of the preretinal neovessels
had R-Ras expression at P17 in the OIR model (Fig. 2A,
Supplementary Fig. S4). This ﬁnding was conﬁrmed by double
immunoﬂuorescent imaging of the retina showing some
preretinal neovessels devoid of R-Ras expression in OIR (Figs.
2E, 2F). By costaining the retinal tissue sections for R-Ras and
endothelial cells, as well as for R-Ras and pericytes, the R-Ras
expression was conﬁrmed to be conﬁned to both endothelial
cells and pericytes (Figs. 2B–G).
FIGURE 2. R-Ras is strongly, but selectively expressed in the endothelial cells and pericytes of blood vessels in retina. Oxygen-induced retinopathy
was induced by exposing WT pups to 75% oxygen at P7 for 5 days and returning them to normal room air at P12. After 5 days in normoxia (at P17),
the R-Ras expression was determined from the revascularized retinas by IHC and immunoﬂuorescence (IF) using R-Ras–speciﬁc primary antibody.
(A) Representative images of R-Ras expression in the OIR model. More than 30% of the preretinal blood vessels are negative for R-Ras (arrow),
whereas blood vessels in retina are R-Ras positive (arrowhead). Right, negative control (no primary antibody). There is also faint R-Ras expression
from other retinal cells, presumably from neural cells in the retina. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer, OPL,
outer plexiform layer; ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segments; RPE, retinal pigment epithelium. (B–E) Representative
confocal images showing the colocalization of R-Ras (green) and CD31 (red) in the retina of frozen sections after immunoﬂuorescence staining. (C)
R-Ras is expressed in the endothelial cells in the retina and (D) also in the preretinal blood vessels. (E) Some of the preretinal blood vessels are
negative for R-Ras. (F) R-Ras is expressed in the pericytes (NG2, red) in the retina. Some pericytes of preretinal blood vessels are negative for R-Ras
in OIR (arrow), but (G) R-Ras is also expressed in the pericytes of preretinal neovessels. Scale bars: 100 lm (A, B), 20 lm (C–G).
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R-Ras Does Not Change the Hypoxic
Revascularization Rate of the Retina
As all of the antiangiogenic molecules used to treat neovascular
retinal diseases have been shown to inhibit sprouting
angiogenesis induced in the OIR model,36–38 the role of R-Ras
in hypoxia-driven neovascularization in the retina was ex-
plored next. First, we determined whether regression of
vessels under hyperoxic conditions in the OIR model is
comparable between R-Ras KO and WT mice. After exposure
to 75% oxygen between P7 and P12, retinas were evaluated at
P12. Typical for this model,39 large areas of the central vascular
network were obliterated, with only a few major vessels
remaining centrally in both WT and R-Ras KO mice
(Supplementary Fig. S5). Quantitative analysis of obliterated
areas in retina conﬁrmed that the retinal vasculature in R-Ras
KO and WT mice are affected in a similar fashion by hyperoxic
exposure (Supplementary Fig. S5). Taken together, these data
suggest that deletion of R-Ras has no observable effect on
vascular regression and remodeling in the retina in response to
hyperoxic conditions.
On return to normoxia, the avascular and hypoxic central
retina stimulates rapid regrowth of vessels.24 The rate of retinal
revascularization in WT and R-Ras KO retinas was determined
by quantifying avascular retinal area 5 days after the mice were
returned to normoxia. There was no signiﬁcant difference in
the avascular retinal area between the WT and R-Ras KO,
indicating that the rate of retinal revascularization is similar
between the WT and R-Ras KO mice at P17 (Fig. 3). In addition
to revascularization of the retina, the strong hypoxic stimulus
from the center of the retina also drives abnormal misdirected
sprouting of blood vessels into the vitreous at the interface
between the centrally obliterated and peripherally perfused
retina.24 Preretinal (i.e., pathologic) neovascularization reaches
its maximum in WT mice 5 days after returning to normoxia (at
P17).24 No signiﬁcant differences in the number of preretinal
neovascular tufts and clusters were found between R-Ras KO
mice and WT mice (Fig. 3). The results indicate that neither the
hypoxia-induced revascularization rate of the obliterated areas
in retina nor the rate of preretinal neovascularization is
affected by R-Ras deletion.
R-Ras Deﬁcient Retinal Blood Vessels Have
Increased Permeability in OIR
It has been recently shown that loss of R-Ras worsens blood
vessel structure and perfusion and the pathologic plasma
leakage in tumor angiogenesis.15,21 In order to assess the role
of R-Ras in controlling the vascular permeability of the retinal
vasculature, the OIR model was used. The vascular leakage was
quantiﬁed by measuring EB dye extravasation from retinal
vessels. The R-Ras KO retinas had approximately 100% increase
in the retinal EB leakage compared with the WT retinas in OIR
(P¼ 0.0223 at 1 hour and P¼ 0.0006 at 24 hours; Figs. 4A–C).
No difference was detected in the amount of EB leakage when
comparing normal WT and R-Ras KO retinas (Supplementary
Fig. S6). To conﬁrm the enhanced retinal leakage in R-Ras KO
animals in OIR, we also measured the amount of IgG heavy
chain molecule accumulation in the retina, as this antibody
subclass is normally compartmentalized within the circula-
tion.40 We could not detect a difference in IgG leakage in the
normal retinas between WT and R-Ras KO animals. A 4-fold
increase in the amount of IgG was detected in the R-Ras KO
retinas over the WT retinas in OIR as a sign of increased
vascular permeability (P ¼ 0.0007; Fig. 4D). To rule out the
possibility that the increased levels of IgG in the R-Ras KO OIR
retinas were due to plasma cells, immunohistologic staining of
CD138/Syndecan-1 was performed. There was no increase in
the number of plasma cells in KO retinas compared to WT in
the OIR samples (Supplementary Fig. S7).
FIGURE 3. Neither revascularization nor pathologic neovascularization is affected by R-Ras deﬁciency in the OIR model. Wild-type and R-Ras KO
mice pups were exposed to hyperoxia as previously described, and retinas were harvested at P17. Areas of vascular obliteration and pathologic
neovascularization (meaning neovascular tufts) were quantiﬁed from Isolectin IB4–stained whole mounts using Adobe Photoshop CS3. (A)
Representative retinas of WT and R-Ras KO mice at P17. The revascularization rate was determined by quantifying the avascular areas (yellow) in
retinal ﬂat mounts. The amount of pathologic neovascularization (tufts, red) was also determined. (B) Summary of quantitative analysis of vascular
obliteration (yellow) and neovascularization (red). The avascular and pathologic neovascularization areas were measured, and results are
represented as an area relative to WT area. Error bars represent 6 95% conﬁdence intervals. (WT: n¼ 63, KO: n¼ 48 retinas.)
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R-Ras Deﬁciency Severely Impairs Pericyte
Coverage of Angiogenic Blood Vessels and Reduces
VE-Cadherin Expression in OIR Model
Close interaction between sprouting endothelium and peri-
cytes is crucial for vessel maturation and stability.41,42
Pathologic, angiogenic vasculature in tumors is characterized
by insufﬁcient pericyte association around the blood vessels.43
Consistent with this notion, a signiﬁcant reduction in the
direct physical contact between pericytes and the endothelium
of blood vessels was found in R-Ras KO retinas in the OIR
model at P17 (Figs. 5A–B). When the pericyte coverage around
the tips of the sprouting angiogenic blood vessels was
quantiﬁed, 40% reduction in the pericyte coverage was
recorded in the R-Ras KO retinas over the WT retinas (P ¼
0.033; Fig. 5C).
Vascular endothelial–cadherin is a member of cadherin
superfamily expressed exclusively on endothelial cells.21 It is a
crucial factor of adherens junctions between the endothelial
cells.15 R-Ras is known to stabilize adherens junctions by
inhibiting VEGF-induced VE-cadherin internalization.15 We
studied the expression of VE-cadherin in OIR model, and we
observed that both the intensity of the VE-cadherin immuno-
staining and colocalization of VE-cadherin with CD31 were
signiﬁcantly reduced in KO mice compared to WT mice (Fig.
5D). Colocalization analysis showed signiﬁcant reduction in
VE-cadherin and CD31 colocalization in R-Ras KO mice
compared to WT mice (overlap coefﬁcient according to
Manders: r ¼ 0.51 for WT, and R ¼ 0.43 for KO (P ¼ 0.04)).
Our ﬁnding on VE-cadherin expression is in line what has been
reported in tumor vasculature of R-Ras KO and WT mice.21
Reduced R–Ras Expression in the Neovessels of
Human Diabetic Retinopathy Correlates With
Increased Vascular Leakage and the Immature State
of the Neovessels
R-Ras expression was restricted exclusively to blood vessels in
normal human retina, and it was expressed in all blood vessels
in normal human retinas (Supplementary Fig. S8). To address
the relevance of our ﬁndings on the role of R-Ras in the OIR
model to human ischemic retinopathies, the pathologic retinal
neovascular membranes that develop in human diabetic
retinopathy patients were studied. These neovascular mem-
branes were collected from patients suffering from type I
diabetes, who had already developed tractional retinal detach-
ment due to ﬁbrosis of neovascular membranes. Thus, the
samples represent the end stage of the disease, where
substantial amount of ﬁbrosis is associated with neovessels,
but they still contain regions with active pathologic angiogen-
esis. In the diabetic neovascular membranes, R-Ras expression
was exclusively restricted to blood vessels (Fig. 6). Like
pathologic preretinal neovessels in the OIR model, human
diabetic neovascular membranes had varying expression of R-
Ras (Fig. 6). Only approximately 80% of the blood vessels in the
human neovascular membranes expressed any R-Ras protein at
all (Fig. 6C). To explore whether R-Ras expression has any
relation to the blood vessel maturity, the human tissue samples
were double-stained for R-Ras and VEGFR2, a marker of blood
vessel immaturity.44,45 A strong inverse correlation between
expression of the two proteins was identiﬁed (Spearman’s q¼
0.821, P ¼ 0.023, R2 ¼ 0.563); the higher the percentage of
immature blood vessels (VEGFR2þ), the less R-Ras expression
there was in the blood vessels (Fig. 6).
To address whether lack of R-Ras in immature blood vessels
inﬂuences vascular permeability in human diabetic neovascu-
lar membranes, samples were stained for HSA. Samples with a
low percentage of R-Ras–expressing blood vessels showed a
strong accumulation of HSA outside the vessels, whereas
samples with a high percentage of R-Ras–expressing blood
vessels had HSA staining restricted mainly inside the vessels
(Figs. 6A–B). There was a strong negative correlation between
area of extravascular HSA and the number of R-Ras–positive
vessels (Spearman’s q: r¼0.886, P¼ 0.019, R2¼ 0.835); the
more vascular leakage outside of the blood vessels, the less R-
Ras expression was in the blood vessels. Furthermore, we
could demonstrate that leaked, extravascular HSA was detected
mainly around individual blood vessels that lack R-Ras (Fig. 7).
This was especially evident in samples that had R-Ras in the
majority of blood vessels as extravascular HSA mainly
accumulated around those few blood vessels devoid of R-Ras
expression (Fig. 7).
DISCUSSION
The present study demonstrates that the small GTPase R-Ras
regulates the pathologic permeability of blood vessels in
hypoxia-driven angiogenesis without altering the rate of
FIGURE 4. R-Ras deﬁciency increases vessel permeability in mouse OIR
model. Wild-type and R-Ras KO mice pups were exposed to hyperoxia
as described previously. The EB dye was injected IP, and retinas and
blood samples were harvested after 1 hour and 24 hours at P17. Evans
Blue concentrations were measured spectrophotometrically at 620 nm,
and EB concentration for each sample was calculated from a standard
curve. Results are expressed as relative to EB concentration in the
plasma. (A) Representative R-Ras KO and WT OIR retinas after systemic
injection of EB dye. In many of the R-Ras KO retinas, EB dye was visible,
whereas most of the WT retinas were colorless. (B) Statistical analysis
of a representative experiment shows a signiﬁcant increase in vascular
leakage in R-Ras KO OIR retinas compared to WT OIR retinas already at
a 1-hour time point (P ¼ 0.0223, *, nonparametric Mann-Whitney U
test, WT n ¼ 6, R-Ras KO n ¼ 8). (C) There is a highly signiﬁcant
difference in vascular leakage between R-Ras KO and WT mice at the
24-hour time point (P ¼ 0.0006, ***, nonparametric Mann-Whitney U
test; WT n¼20, R-Ras KO n¼18). Error bars represent SEM. To assess
the IgG protein accumulation, OIR retinas were harvested at P17,
proteins were extracted and samples were electrophoresed on gradient
gels, and Western blotting was done using anti-mouse IgG antibody. (D)
Representative images of immunoblotting from where mouse IgG
heavy chain densities were quantiﬁed and normalized against GAPDH.
Relative comparison of IgG heavy chain protein from WT OIR and R-
Ras KO OIR samples gives a 3.5-fold difference (P ¼ 0,0007, ***,
nonparametric Mann-Whitney U test). There is no difference in the IgG
protein level between healthy WT and KO mice at P17 (P ¼ 0.7879).
Error bars represent 6 95% conﬁdence intervals. (WT: n¼ 6, KO: n¼
6, WT OIR: n¼ 14, KO OIR: n ¼ 16.)
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revascularization of the hypoxic retina. Furthermore, by
analyzing a set of preretinal vascular membranes obtained
from diabetic retinopathy patients, we were able to demon-
strate that neovascular membranes with reduced R-Ras
expression in immature vessels display increased pathologic
vascular leakage. Given that increased vascular leakage is the
pathognomonic feature in human diabetic retinopathy, our
study implicates that loss of R-Ras may have a pathologic role in
this disease.
R-Ras reduced the pathologic vascular permeability in
ischemia-induced retinopathy without inhibiting retinal angio-
genesis, whether it was developmental or induced by hypoxia
in OIR. This is a clear difference to all current available
antiangiogenic therapies that have been shown to function in
OIR by inhibiting sprouting angiogenesis.36 Furthermore, the
mechanism of resistance to the currently available antiangio-
genic therapies both in tumors and retinopathy is actually
related to the eradication of the neovessels, which, in turn,
worsens the underlying ischemia and drives the formation of
new, leaky blood vessels by alternative molecular mecha-
nism.13 Thus, the proposed molecular mechanism for future
antiangiogenic therapies is one in which the angiogenic blood
vessels are ‘‘normalized’’ to stable ones to alleviate the hypoxia
and stop the detrimental aberrant vascular leakage.46,47 Taken
with earlier demonstrations of a causal relationship between R-
Ras expression and vessel maturation,15,20,48,49 our results
suggest potential utility of R-Ras in treating retinopathies
involving angiogenesis. Modulating R-Ras expression repre-
FIGURE 5. Pericyte coverage and VE-cadherin expression is reduced in R-Ras KO in the OIR model in angiogenic retinal blood vessels. Oxygen-
induced retinopathy was induced in WT and R-Ras KO mice as described previously. Retinas were harvested at P17, and whole-mount retinas were
double-stained with Alexa Fluor–conjugated Isolectin IB4 and with an antibody against the pericyte marker NG2 proteoglycan. Three-dimensional
images were taken from the most superﬁcial vascular plexus at the tips of the blood vessels from the region where vessels grow toward the optic
nerve. (A) Representative images of WT and R-Ras KO blood vessel endothelial cells (red) surrounded by pericytes (green). (B) The majority of
images from WT mice retina had a lot of pericytes around the blood vessels, whereas the majority of pictures taken from the KO retinal blood
vessels were lacking or had very few pericytes. (C) Direct contact between endothelial cells and pericytes was quantiﬁed by colocalization analysis.
The result is shown as a percentage of endothelial cell area colocalized with pericytes in WT and R-Ras KO retinal blood vessel tips. The pericyte
coverage is signiﬁcantly reduced in R-Ras KO animals compared to WT by 40% (P ¼ 0.033, *). Error bars represent 6 95% conﬁdence intervals.
(WT: n ¼ 15; R-Ras KO: n ¼ 15. Two pictures were taken from each retina, and an average was calculated). The expression of VE-cadherin was
studied in the OIR model by staining frozen cross-sections of retina with antibodies against VE-cadherin and endothelial cells (CD31). The intensity
as well as the colocalization of VE-cadherin staining with endothelial cells was quantiﬁed using BioImageXD. (D) Representative images of VE-
cadherin (green) and CD31 (red) in P17 OIR model in WT and R-Ras KO are presented. Colocalization analysis showed signiﬁcant reduction in VE-
cadherin and CD31 colocalization in R-Ras KO mice compared to WT mice (overlap coefﬁcient according to Manders: r¼ 0.51 for WT and R¼ 0.43
for KO [P¼ 0.04]), n¼ 5 mice for WT and n ¼ 5 mice for KO.
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sents a novel therapeutic approach that may be capable of
addressing pathologic vascular permeability without simulta-
neously worsening the underlying pathobiology of the
disease— hypoxia.
The differences between the mechanisms of R-Ras and
other antiangiogenic therapies are evidenced by a recent
report implicating activated Ras signaling as a key mediator of
pathologic neovascularization induced by many cytokines and
growth factors, including VEGF, in blinding neovascular eye
diseases.22 Westenskow et al.22 reported that aberrant Ras
signaling can be inhibited by a molecule called p120RasGAP.
The inhibitory function of p120RasGAP on Ras-driven retinal
neovascularization was shown to take place through the
inhibition of sprouting angiogenesis.22 In contrast, R-Ras
functions in the retina primarily to stabilize vasculature and
prevent leakage and does not inhibit sprouting angiogenesis in
OIR. The mechanistic differences between R-Ras and p120Ras-
FIGURE 6. Reduced R-Ras expression correlates with leakage of human serum albumin in human diabetic retinopathy vasculature, and it is
negatively correlated with VEGFR2 expression. Preretinal neovascular membranes obtained from vitrectomies from diabetic retinopathy patients
were analyzed by immunohistochemistry for their protein expression. Immunohistochemical staining from adjacent sections was done with anti-
CD31þ anti–R-Ras, anti-HSA, and anti–R-Rasþ anti-VEGFR2 antibodies. The number of R-Ras–positive vessels was calculated from R-Ras and CD31
double-stained sections (n¼7; 5–9 different sections analyzed from each sample). Correlation analysis between R-Ras and VEGFR2 was done from R-
Ras þ VEGFR2 double-stained sections and compared to CD31 staining from adjacent sections (n ¼ 7; 5–9 different sections analyzed from each
sample). Vascular membranes with strong R-Ras expression show limited extravascular staining for HSA (A), whereas samples with weak R-Ras
expression show strong staining for HSA outside the blood vessels (B). Scale bars: 100 lm. There is a strong inverse correlation between HSA-
positive extravascular area and the percentage of R-Ras–positive neovessels (Spearman’s q: r¼0.886, P¼ 0.019, *, R2¼ 0.835, n¼ 6 patients) (D).
(C) Approximately 20% of the neovessels do not express any R-Ras at all (R-Ras–positive vessels 81 6 10%, meanþ SD, n¼ 6 patients). Data are
shown as a box plot with median and 95% conﬁdence interval. (E, F) Double-staining for R-Ras and VEGFR2 shows an inverse correlation
(Spearman’s q: r¼0.821, P¼ 0.023, R2¼ 0.563) between the number of R-Ras–expressing and VEGFR2-positive blood vessels. When a majority of
blood vessels has R-Ras expression, a majority of blood vessels are negative for VEGFR2 expression, whereas the VEGFR2 expression is opposite
when very few blood vessels express R-Ras. Scale bars: 200 lm.
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GAP are further highlighted by the fact that p120RasGAP
actually inhibits R-Ras.50
R-Ras has recently been proposed as a master regulator of
transendothelial permeability in angiogenesis.15,21,51 Our
understanding of the molecular mechanisms by which R-Ras
exerts its biological effects on endothelial cells has increased
recently.15,48 It has been demonstrated that R-Ras suppresses
endothelial cells’ response to VEGF by inhibiting internaliza-
tion of VEGFR2 that is required for full activation of the
receptor49 as well as by inhibiting VEGFR2-p38MAPK-HSP27
signaling axis.51 However, the biological effects of R-Ras in
angiogenesis cannot be solely attributed to the inhibition of the
VEGF signaling because VEGF inhibitors have been shown to
function in OIR by inhibiting sprouting angiogenesis,36,37
whereas R-Ras is known to promote endothelial cell survival.20
In addition to the inhibition of VEGF, it has been demonstrated
that R-Ras forms a complex with Rab interactor 2 protein and
Rab5, and then this complex activate Rac1, which in turn
activates integrins to promote endothelial cell adhesion to
surrounding ECM.52,53 R-Ras also interacts with ﬁlamin A,
FIGURE 7. Vascular leakage is mainly from blood vessels that do not express R-Ras in human diabetic retinopathy. The preretinal membranes from
human diabetic retinopathy patients were either stained for CD31, double-stained for CD31 (green) and R-Ras (brown) or stained for HSA (brown).
(A) Blood vessels in preretinal membranes stained for endothelial cells (CD31, brown). (B) Double-staining of blood vessels (CD31, green) and R-Ras
(brown) expression. (C) Vascular leakage was determined by using an antibody against HSA (brown). Red boxes on ﬁgures on the left are presented
as high magniﬁcation pictures on the right. (B and C) No vascular leakage (restricted HSA staining only inside the neovessels) can be seen around
neovessels with strong R-Ras expression. Conversely, the blood vessels that do not express any R-Ras show aberrant vascular permeability around
them. Arrows represent R-Ras–negative blood vessels. Scale bars on the left represent 450 lm and 200 lm on the right.
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which is crucial for maintaining of endothelial barrier
function.54 Furthermore, actin-binding protein Girdin/GIV
regulates transendothelial permeability by controlling VE-
cadherin trafﬁcking through R-Ras.48 In the present study, we
conﬁrmed a previous ﬁnding that R-Ras is required for
recruitment of pericytes around endothelial cells,21 which is
crucial for blood vessel stabilization.41 In accordance with
previous studies on tumors, we demonstrated that R-Ras
deﬁciency reduces VE-cadherin expression in endothelial cells,
which may result in increased vessel leakiness in R-Ras–
deﬁcient mice.21
We demonstrate that angiogenic blood vessels, especially
immature VEGFR2þ vessels, show reduced expression of R-Ras
in human diabetic neovascular membranes, and the reduced R-
Ras expression correlates with increased vascular leakage from
the neovessels of human diabetic vasculature. We suggest that
reduced vascular R-Ras expression is a critical feature in the
pathogenesis of human diabetic retinopathy, especially in the
accumulation of retinal edema. Thus, R-Ras represents a
promising new therapeutic target to address angiogenesis-
related pathologic vascular permeability.
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Supplementary Figure S1 
 
Supplementary Figure S1. Rras mRNA expression increases along the maturation of retinal 
vasculature. Retinal vasculogenesis was analyzed from normal mice at different time points (P0 – 
P22) during the development of retinal vasculature. Retinas were subjected to either quantitative 
mRNA (qPCR) or protein (western blotting) analysis as described in Figure 1. (A) The graph shows 
a pattern of relative Rras mRNA expression in the retina during development. The fold change in 
mRNA expression level is relative to P0 expression level (2
-¨¨Ct
 method). On the X-axis is the 
postnatal day on which gene expression was measured. Error bars represent ± 95% confidence 
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intervals of the fold change (calculated from the ¨¨Ct values and the limits has been anti-logged to 
get the confidence limits for the fold changes). (At P0 n=2, at other time points n=3 – 5.) (B) The R-
Ras protein expression densitometry shows a similar pattern, where the expression peaks at P17 and 
drops thereafter. (p=0,016, *; P4, P7, P17 and P22 n=5, P12 n=4). The samples presented above 
were run on the same gel. Representative samples cropped and presented side-by-side. 
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Supplementary Figure S2 
 
Supplementary Figure S2. Maturation and remodeling of the retinal vasculature.  WT retinas 
from different time points (P12, P17 and P22) were dissected and fixed with 4% PFA. Retinas were 
stained with Alexa Fluor conjugated Isolectin IB4 and imaged with confocal microscopy. (A) 
Representative images of sections of whole mounted retinas show a decrease in the intensity of the 
Isolectin IB4 signals at P12 onwards. (B) All retinal vascular plexuses (superficial, intermediate and 
deep) show decreased intensity of Isolectin IB4. 
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Supplementary Figure S3 
 
Supplementary Figure S3. The developmental rate of retinal angiogenesis is not affected by R-
Ras deficiency. Eyes were harvested from healthy mice at P0-P6 when the development of the 
superficial vascular plexus occurs. Retinas were fixed with 4% PFA and stained with Alexa Fluor 
conjugated Isolectin IB4. (A) The rate of early angiogenesis was quantified in retinal flat mounts by 
measuring the length of vasculature from the optic nerve to the tips of the blood vessels. Four 
measurements per retina were taken and an average was calculated. The length of angiogenic 
vasculature of superficial vascular plexus is the same in WT and R-Ras KO retinas at all analyzed 




time points. Scale bar represents 500 ȝm. (B) There is no significant difference in the length of 
vasculature in superficial vascular plexus between WT and R-Ras KO mice during development 
(NS, student´s t-test). Error bars represent SDs. (WT n=41, R-Ras KO n=33) 
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 Supplementary Figure S4 
 
Supplementary Figure S4. R-Ras expression in retina during development and oxygen 
induced retinopathy (OIR). Strong R-Ras expression can be seen from the retinal blood vessels, 
while a faint expression is seen from neurons during normal development at P12 and P17. R-Ras 
expression decreases from the retina after 5 days exposure to 75 % oxygen (P12 OIR). On return to 
normoxia, strong R-Ras expression can be seen in the blood vessels that re-vascularize the retina, 
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whereas some of the preretinal neovessels are negative for R-Ras expression in OIR mouse model 
(P17 OIR). Both R-Ras KO retinas (R-Ras KO P17 OIR) and negative immunohistochemical 
control show no R-Ras staining at P17 in OIR model. Eyes were harvested at P12 and P17 during 
normal development and in OIR model.  
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Supplementary Figure S5 
 
Supplementary Figure S5. R-Ras deficiency doesn’t affect vascular regression in OIR model. 
WT and R-Ras KO mice pups were exposed to 75% hyperoxia for 5 days. Retinas were harvested 
right after the return to normoxia to quantify the degree of vascular regression. (A-B) Quantitative 
analysis of avascular areas (inside the line) at P12 shows that the vascular regression is similar in 
WT and KO animals. Error bars represents SDs. (WT n=10, KO n=8.) 
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Supplementary Figure S6 
 
 
Supplementary Figure S6. There is no difference in vessel permeability in the retinas of 
healthy WT and R-Ras KO mice. To see whether there is vascular leakage in healthy R-Ras KO 
animals the Evans Blue dye was injected to WT and R-Ras KO animals and let circulate for 24 
hours.  Retinas were harvested and plasma samples taken and all samples were incubated in N, N-
Dimethylformamide overnight at 78 °C. Evans Blue dye concentration depicting the leakage was 
measured spectrophotometrically at 620 nm and EB concentration in the retina relative to EB 
concentration in the plasma was calculated. Graph shows that there is no difference in the vascular 
permeability between healthy WT and R-Ras KO animals. Error bars represent SEM. (p=0.2398, 
WT n=7, KO n=8 retinas) 
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Supplementary Figure S7 
 
Supplementary Figure S7. The number of plasma cells is not increased in the R-Ras KO mice 
retina in oxygen-induced retinopathy. Plasma cell marker CD138 (1:500) and hematoxylin IHC 
stainings were done for P17 harvested OIR model retinas. (A-B) Representative images of WT and 
R-Ras KO mice retinas at P17 in the OIR model. Absence of plasma cells both in WT and KO 
retinas rules out the possibility that the increased levels of IgGs in the R-Ras KO OIR retinas are 
due to increased levels of plasma cells. (C) Positive control (gut) for CD138 (1:500) showing strong 
signal (brown) and (D) negative control (no primary antibody). Scale bars represent 50 ȝm. 
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Supplementary Figure 8. R-Ras is expressed by all blood vessels in normal human retina. 
Normal retinas were collected from two patients whose eyes were enucleated due to choroidal 
melanoma. The R-Ras expression and blood vessels were determined from the retinas by double-
immunofluorescence using R-Ras (green) and CD31 (red) specific primary antibodies and then 
studied by confocal microscope. (A) Representative image of R-Ras expression in normal human 
retina. R-Ras is restricted exclusively to blood vessels and all of the blood vessels are positive for 
R-Ras (B) Representative confocal image showing the expression of R-Ras (green) and blood 
vessels (red) in another normal retina. All of the blood vessels express R-Ras also in this sample. 
Scale bars represent 200 ȝm. 
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A B S T R A C T
Ischemic retinopathy is a vision-threatening disease associated with chronic retinal inﬂammation and hypoxia
leading to abnormal angiogenesis. Furin, a member of the proprotein convertase family of proteins, has been
implicated in the regulation of angiogenesis due to its essential role in the activation of several angiogenic
growth factors, including vascular endothelial growth factor-C (VEGF-C), VEGF-D and transforming growth
factor - β (TGF- β). In the present study, we evaluated expression of furin in the retina and its role in retinal
angiogenesis. As both inﬂammation and hypoxia contribute to angiogenesis, the role of furin was evaluated
using myeloid-cell speciﬁc furin knockout (KO) mice (designated LysMCre-fur(ﬂ/ﬂ)) both in developmental ret-
inal angiogenesis as well as in hypoxia-driven angiogenesis using the oxygen-induced retinopathy (OIR) model.
In the retina, furin expression was detected in endothelial cells, macrophages and, to some extent, in neurons.
The rate of angiogenesis was not diﬀerent in LysMCre-fur(ﬂ/ﬂ) mice when compared to their wild-type littermates
during development. In the OIR model, the revascularization of retina was signiﬁcantly delayed in LysMCre-
fur(ﬂ/ﬂ) mice compared to their wild-type littermates, while there was no compensatory increase in the preretinal
neovascularization in LysMCre-fur(ﬂ/ﬂ) mice. These results demonstrate that furin expression in myeloid cells
plays a signiﬁcant role in hypoxia-induced angiogenesis in retina.
1. Introduction
Ischemic retinopathies, such as retinopathy of prematurity (ROP),
proliferative diabetic retinopathy (PDR), and retinal vein occlusion
(RVO) are major causes of visual impairment and blindness in in-
dustrialized countries (Fong et al., 2004; Jonas et al., 2017; Reynolds,
2014). Retinal ischemia induces the stabilization of a transcription
factor hypoxia inducible factor-1α (HIF-1α), which turns on the ex-
pression of a large number of angiogenic genes such as vascular en-
dothelial growth factor (VEGF) (Campochiaro, 2015). This leads to
retinal neovascularization associated with vitreous hemorrhages and
ﬁbrosis of neovascular membranes causing tractional retinal detach-
ment and, ultimately, blindness (Campochiaro, 2015).
Retinal ischemia is also associated with inﬂammatory manifesta-
tions. Hypoxia attracts macrophages into hypoxic areas (Mitamura
et al., 2005; Tsutsumi et al., 2003) where the hypoxia-activated mac-
rophages and microglia, the immune cells of the retina, release not only
proinﬂammatory but also angiogenic cytokines. In diabetic retinopathy
(DR), both invading macrophages and resident microglia have been
implicated in the pathogenesis of the retinopathy retinopathy
(Abcouwer, 2012). Of note, macrophages have been shown to be the
main source of VEGF-C in the retina. In the retina, VEGF-C signaling
pathway regulates the branching of blood vessels (Tammela et al.,
2011). VEGF-C is initially synthesized as an inactive precursor and re-
quires activation by a proprotein convertase subtilisin/kexin (PCSK)
family member furin to become biologically active (Siegfried et al.,
2003b).
Proprotein convertase subtilisin/kexin (PCSK) family enzymes are a
family of nine proteases (PCSK1-2, furin, PCSK4-7, MBTPS1, PCSK9)
that cleave and convert their immature target proteins into biologically
active forms by catalyzing endoproteolytic cleavage at a target site
typically made up of the basic amino acids arginine and lysine
(Turpeinen et al., 2013). Accordingly, PCSK enzymes play a key reg-
ulatory role in a multitude of biological events governed by the growth
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factors (Turpeinen et al., 2013). Among the PCSK family members,
furin is a ubiquitously expressed prototypical serine endoprotease re-
cently implicated to play a key role in various biological processes such
autoimmunity and inﬂammation, and various human diseases (Oksanen
et al., 2014; Pesu et al., 2008; Turpeinen et al., 2013; Vähätupa et al.,
2016a). In ﬁbrovascular tissue from PDR patients, furin expression was
shown to co-localize with one of its cleavage targets, a (pro)-renin re-
ceptor protein, whose expression level is elevated in PDR and asso-
ciated with angiogenic activity, suggesting that furin cleavage has a role
in DR (Kanda et al., 2012).
In addition to VEGF-C (Khatib et al., 2010; Siegfried et al., 2003a),
furin is also required for the activation of a large number of other
proangiogenic growth factors, such as VEGF-D (McColl et al., 2007),
platelet derived growth factors A and B (PDGF-A and –B) (Siegfried
et al., 2003b, 2005), bone morphogenetic protein-4 (BMP-4) (Cui et al.,
1998) and transforming growth factor-β (TGF-β) (Dubois et al., 2001).
On the other hand, the expression of furin itself can be induced by
hypoxia, as it is one of the target genes of HIF-1α (Ma et al., 2017;
McMahon et al., 2005; Silvestri et al., 2008). Despite being linked to
angiogenesis, the functions of furin in these processes are still poorly
known, but the phenotype of the total furin knockout (KO) mice,
lethality during embryonal development due to cardiovascular defects,
suggested blood vessel speciﬁc functions (Roebroek et al., 1998;
Scamuﬀa et al., 2006). This notion was conﬁrmed by endothelial spe-
ciﬁc furin KO that also led to embryonal death due to vascular defects,
and by the endothelial cells lacking furin that were unable to grow
ex vivo (Kim et al., 2012).
As endothelial cells lacking furin cannot grow at all (Kim et al.,
2012), we decided to elucidate the role of furin on retinal angiogenesis
by addressing the expression of furin in the retina and by assessing the
eﬀect of myeloid cell-derived furin on retinal angiogenesis using furin
conditional KO mice (myeloid cell-speciﬁc furin KO; LysMCre-fur(ﬂ/ﬂ)).
The eﬀect of myeloid cells-derived furin on angiogenesis was studied in
developmental retinal angiogenesis, as well as in hypoxia-induced an-
giogenesis in a mouse-model for oxygen-induced retinopathy (OIR),
which is the most widely used model for ischemic retinopathies
(Connor et al., 2009; Smith et al., 1994). In the OIR model, both re-
cruited, blood-derived macrophages as well as the resident macro-
phages of the retina, microglia, have been shown to participate in the
regulation of angiogenesis (Checchin et al., 2006; Gao et al., 2016;
Kataoka et al., 2011; Zhou et al., 2015).
2. Results
2.1. Furin is expressed in macrophages and retinal microglia
Using data from published genome-wide expression studies, the
retinal-cell speciﬁc E-GEOD-33089 experiment and the much wider
searching FANTOM project, we extracted expression data for furin in
cells related to retina. In the larger, but far less speciﬁc, FANTOM
project cDNA analysis of furin expression showed the highest values in
monocyte derived macrophages (Fig. 1A). In the retinal cell-speciﬁc
experiment, based on 155 samples analyzed by microarray, the highest
furin expression was found in microglia (Fig. 1B).
2.2. Furin is expressed in the retina during development and in the OIR
model
To further study the role of furin on retinal angiogenesis in vivo, we
ﬁrst determined a temporal and spatial expression proﬁle of furin in WT
mice during development and in the OIR model. Immunohistochemistry
showed a few cells with weak expression of furin in retina at P4
(postnatal day 4), and thereafter the expression of furin was sub-
stantially stronger from P7 onwards at all studied time points during
development (Fig. 1C). In the OIR model, strong expression of furin was
detected in the vascular layers of the retina at P14 and P17 (Fig. 1D).
Using double-immunohistochemistry for furin and for endothelial cells
marker CD31 as well as for furin and macrophage marker F4/80, furin
expression was localized to endothelial cells (Fig. 1E–F) in the retina
and in the preretinal vascular tufts as well as to macrophages sur-
rounding blood vessels (Fig. 1G–H) in OIR retinas. In addition to these
cells, furin immunoreactivity was also detected in neurons in the retina
(Fig. 1).
2.3. Lack of furin in myeloid cells does not inﬂuence the rate of
developmental angiogenesis
To investigate the role of furin in angiogenesis, we studied mice
deﬁcient for furin gene expression in myeloid cells (LysMCre-fur(ﬂ/ﬂ))
and their respective wild-type littermates (LysM WT) during develop-
mental retinal angiogenesis and during ischemia induced retinal an-
giogenesis using oxygen-induced retinopathy model (OIR). LysMCre-
fur(ﬂ/ﬂ) mice are fertile without no obvious morphological abnormal-
ities (Cordova et al., 2016), and their eyes appear normal upon histo-
logical examination. As total depletion of resident retinal macrophages
has been shown to slow down the rate of developmental retinal an-
giogenesis (Checchin et al., 2006), we ﬁrst explored whether myeloid
cell derived furin inﬂuences the rate of superﬁcial vascular plexus
formation (developmental angiogenesis) in retinas from P6 LysM WT
and LysMCre-fur(ﬂ/ﬂ). In P6 neonatal mice, the diameters of retinal
superﬁcial vascular plexuses were similar and no diﬀerences in either
the number of branching points or ﬁlopodia count were detected be-
tween LysMCre-fur(ﬂ/ﬂ) and LysM WT mice, indicating that furin ex-
pression by myeloid cells does not have a major inﬂuence on in vivo
angiogenesis during neonatal development (Fig. 2A–E). This ﬁnding is
in line with the above reported appearance of furin at the late stages of
retinal vascular development (Fig. 1C).
2.4. Mice deﬁcient for furin expression in myeloid cells show reduced
hypoxic revascularization rate of the retina
The role of myeloid cell derived furin in hypoxia-driven neovascu-
larization in the retina was explored next. First, we determined whether
regression of vessels under hyperoxic conditions in the OIR model is
comparable between LysMCre-fur(ﬂ/ﬂ) and LysM WT mice. After ex-
posure to 75% oxygen between P7 and P12, retinas were evaluated at
P12. Typical for this model (Smith et al., 1994; Uusitalo-Järvinen et al.,
2007; Vähätupa et al., 2016b), large areas of the central vascular net-
work were regressed with only a few major vessels remaining centrally
in both LysM WT and LysMCre-fur(ﬂ/ﬂ) mice (Fig. 2F). Quantitative
analysis of vaso-obliterated areas in retina conﬁrmed that the retinal
vasculature in LysMCre-fur(ﬂ/ﬂ) and LysM WT mice was similarly af-
fected by hyperoxic exposure (Fig. 2G). Taken together, these data
suggest that deletion of furin from myeloid cells has not a signiﬁcant
eﬀect on vascular regression in OIR model.
On return to normoxia, the avascular central retina becomes hy-
poxic and stimulates rapid regrowth of vessels (Smith et al., 1994;
Uusitalo-Järvinen et al., 2007). The rate of retinal revascularization in
LysM WT and LysMCre-fur(ﬂ/ﬂ) retinas was determined by quantifying
the avascular retinal area 5 days after the mice were returned to nor-
moxia. There was a statistically signiﬁcant diﬀerence in the avascular
retinal area between the LysM WT and LysMCre-fur(ﬂ/ﬂ) mice at P17
showing that the rate of retinal revascularization is substantially (30%)
reduced in mice where furin is depleted from myeloid cells (Fig. 2J). In
addition to revascularization of the retina, the strong hypoxic stimulus
from the center of the retina also drives abnormal misdirected sprouting
of blood vessels towards the vitreous at the interface between the
centrally obliterated and peripherally perfused retina (Smith et al.,
1994; Uusitalo-Järvinen et al., 2007). This pathological, preretinal
neovascularization reaches its maximum 5 days after return to nor-
moxia (at P17). There was no statistically signiﬁcant diﬀerence in the
amount of preretinal neovascularization between LysM WT and
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LysMCre-fur(ﬂ/ﬂ) retinas (Fig. 2K). The results indicate that myeloid cell
expressed furin has a role in hypoxia-induced revascularization in re-
tina, but does not inﬂuence the pathological preretinal neovascular-
ization.
3. Discussion
The present study demonstrates that macrophages associated with
retinal blood vessels express furin and the lack of furin in myeloid cells
delays hypoxia-driven angiogenesis in retina. It has previously been
shown that the endothelial speciﬁc deﬁciency of furin leads to embry-
onal death due to vascular defects (Roebroek et al., 1998), and the
cultured endothelial cells lacking furin cannot grow (Kim et al., 2012).
Our results conﬁrm an important role for furin in angiogenesis as we
show for the ﬁrst time that furin deﬁciency in myeloid cells leads to
impaired angiogenesis in hypoxia-induced retinal angiogenesis.
Previous studies have shown that resident macrophages, microglia,
are needed for proper angiogenesis in retina during both developmental
and hypoxia-induced angiogenesis (Checchin et al., 2006). In this study,
we demonstrate that myeloid-cell speciﬁc deletion of proprotein con-
vertase furin leads to the attenuation of angiogenesis and reduced
vascularization rate in OIR model. Among furin's target proteins are
several proangiogenic growth factors, including VEGF-C which is ex-
pressed in macrophages and has a role in controlling the branching of
blood vessels in the retina (Siegfried et al., 2003a; Tammela et al.,
2011). VEGF-A, in turn, does not require activating cleavage by furin.
Interestingly, a myeloid-cell speciﬁc ablation of VEGF-A expression
does not change the VEGF levels in the OIR and does not have any
inﬂuence on angiogenesis in the OIR model (Liyanage et al., 2016).
Although further studies concerning the role of furin in retinal angio-
genesis are required, our results suggest that the expression of furin in
macrophages may be related to activation of proangiogenic growth
factors by furin in the retina. This is in line with previous studies
showing simultaneous induction of VEGF-C and furin expression in
diﬀerent disease models (Khatib et al., 2010; Lopez de Cicco et al.,
2004; Siegfried et al., 2003a).
A major function of furin is to control the bioavailability of anti-
inﬂammatory TGF-β1 (Pesu et al., 2008). As a matter of fact, both furin
and TGF-β are involved in the regulation of each other's activity; furin is
needed for the activation of diﬀerent TGF-β isoforms from inactive
precursor molecules to active, mature forms (Pesu et al., 2008; Ventura
et al., 2017). The active TGF-β2, in turn, induces furin expression
(Ventura et al., 2017). Thus, together they generate a self-sustaining
loop for high TGF-β activity (Ventura et al., 2017). TGF-β signaling is
associated with neovascularization in many diseases, including neo-
vascular ocular diseases (Amin et al., 1994; Bai et al., 2014; Wang et al.,
2017). The expression of TGF-β is elevated in the OIR model, suggesting
that TGF-β signaling contributes to retinal revascularization
(Yingchuan et al., 2010). A previous study has shown that the TGF-β1
bioactivity is reduced in mice deﬁcient in furin expression in myeloid
cells (Cordova et al., 2016). Thus, another plausible explanation for the
reduction of revascularization in the retina of LysMCre-fur(ﬂ/ﬂ) mice
could be the reduced bioavailability of TGF-β due to lack of activating
furin.
Although retinal revascularization rate and the formation of pa-
thological preretinal tufts are inter-related in the OIR model, we
identiﬁed a delayed revascularization rate in retina without a sub-
sequent increase of pathological preretinal tuft formation in LysMCre-
fur(ﬂ/ﬂ) mice in the OIR model. One explanation is that resident mac-
rophages, microglia, persist in the retina in response to ﬁve-day long
hyperoxia despite blood vessels disappearing completely from retina
(Davies et al., 2006). Once the revascularization is initiated upon return
to normoxia, i.e. induction of hypoxia in retina, resident microglial cells
respond to hypoxia by secreting proangiogenic growth factors and di-
rect the revascularization, but selectively only in retina, where they are
located. This notion is supported by the facts that the microglia are
mainly located in the avascular areas after the hyperoxia-period and the
function of macrophage-derived VEGF-C is to convert the tip cells to
stalk cells during retinal angiogenesis (Tammela et al., 2011). The lack
of inﬂuence on preretinal pathological revascularization in the
LysMCre-fur(ﬂ/ﬂ) mice is rather striking because we observed sig-
niﬁcantly larger avascular areas in LysMCre-fur(ﬂ/ﬂ) mice than in WT
mice. This, in turn, should theoretically induce more pronounced
compensatory preretinal pathological tuft formation, but we could not
demonstrate that. An explanation why larger avascular retinal area
does not translate into enhanced preretinal neovascularization, may be
impaired proangiogenic growth factor activation in LysMCre-fur(ﬂ/ﬂ)
mice.
Taken together our study demonstrates that the lack of furin in
myeloid cells delays hypoxia-driven angiogenesis in retina and im-




Monocyte/Macrophage-speciﬁc furin conditional knockout
LysMCre-fur(ﬂ/ﬂ) was generated as described previously (Cordova et al.,
2016). Brieﬂy, mice bearing ﬂoxed fur alleles were backcrossed six
times with C57BL/6 mice. LysMCre mice on C57BL/6 background were
purchased from Taconic. LysMCre mice were bred with fur(ﬂ/ﬂ) animals
to generate myeloid-speciﬁc furin knockout mice LysMCre-fur(ﬂ/ﬂ).
Mice were housed under pathogen-free standard conditions, bred and
the genotype was determined by PCR. Mice were fed with standard
laboratory pellets and water ad libitum. All animal experiments were
performed according to the ARVO statement for the use of animals in
ophthalmic and vision research in accordance with protocols approved
by the National Animal Ethics Committee of Finland.
4.2. Oxygen-induced retinopathy (OIR) model
The experiments on OIR model were carried out as described in
detail previously (Smith et al., 1994; Stahl et al., 2010b; Uusitalo-
Järvinen et al., 2007; Vähätupa et al., 2016b). Brieﬂy, neonatal mice at
P7 and their nursing mother were exposed to 75% oxygen for 5 days. At
P12, the mice were returned to normal room air. Animals were eu-
thanized at P12 to assess the degree of vascular regression and at P17 to
determine the rate of retinal revascularization and preretinal neo-
vascularization. As postnatal weight gain has been shown to aﬀect
outcome in the OIR model, the pups included in the study were weight-
matched (Stahl et al., 2010a).
Fig. 1. Furin is expressed by the endothelial cells and macrophages in retina. Using expression data from the FANTOM 5 project, cDNA expression data was extracted for the primary
furin CAGE for relevant cell types (A). Expression data for furin in diﬀerent retinal cell types was extracted from previously performed microarray expression analysis (B). In panels A–B
the cell types are sorted by increasing average expression from left to right. Furin expression from retina was determined during developmental angiogenesis at P4, P7 and P14 and in OIR
model at P14 and P17 from the revascularized retinas by IHC and IF using furin speciﬁc antibody. Representative images of furin expression during development (C) and in the OIR model
(D). Arrows are pointing furin speciﬁc staining at P17 OIR. Scale bars represents 100 μm. Representative confocal images showing CD31 positive endothelial cells (red) and furin (green)
(E–F) and F4/80 positive macrophages (red) and furin (green) (G–H) in the retina of frozen sections after immunoﬂuorescence staining. Panels E and G are showing stainings at 20×
magniﬁcation and panels F and H at 63× magniﬁcation. Arrows are pointing the endothelial cells or macrophages that are expressing furin. Arrowheads are pointing neovascular tufts.
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segments; RPE,
retinal pigment epithelium. Scale bars represents 100 μm in E and G and 20 μm in F and H.
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4.3. FANTOM analysis of retinal cell types
The FANTOM project has performed expression analysis on 1839
samples from 573 primary cells, 152 tissues, and 250 cell lines in
human. Speciﬁcally, the data comes from cap analysis gene expression
(CAGE) sequencing of cDNA (FANTOM Consortium et al., 2014). Ex-
pression data was extracted for the primary furin CAGE for relevant cell
types: endothelial cells, pericytes, astrocytes, retinal pigment epithe-
lium cells, neurons, neutrophils, endothelial progenitor cells, corneal
epithelial cells and monocyte derived macrophages.
4.4. Microarray analysis of retinal cell types
A microarray expression analysis of mouse genes in various retinal
cell type groups was performed previously and is stored as accession E-
GEOD-33089 on the ArrayExpress database (https://www.ebi.ac.uk/
arrayexpress/experiments/E-GEOD-33089). From the data we ex-
tracted furin gene expression values for 155 samples across 7 cell type
groups: amacrine, cone, rod, bipolar, horizontal, ganglion, and micro-
glia (Siegert et al., 2012). Both FANTOM and microarray analyses were
performed utilizing supercomputer resources provided by CSC–IT
Center for Science of the Finnish Ministry of Education and Culture and
the raw data was processed as previously described in detail elsewhere
(Barker et al., 2017).
4.5. Immunohistochemistry (IHC) and isolectin GS-IB4 staining
For immunohistochemistry, the eyes were ﬁxed with 4% PFA and
embedded in paraﬃn (for IHC), or freshly frozen in OCT embedding
compound in liquid nitrogen cooled isopentane and later ﬁxed with
methanol (for immunoﬂuorescence). The IHC stainings were carried
out on 4–6 μm thick tissue sections using the following primary anti-
bodies: rabbit anti-furin, (H-220), (Santa Cruz Biotechnology, Dallas,
TX), rat anti-CD31 (BD Pharmingen, San Diego, CA) and rat anti-F4/80
(Life Technologies, Paisley, UK) followed by horseradish peroxidase
(HRP) or ﬂuorescein-conjugated secondary antibodies. Hematoxylin
staining was used as a counterstain. IF samples were mounted with
Vectashield mounting medium with DAPI (Vector Laboratories,
Burlingame, CA) and images were taken with confocal microscope (Carl
Zeiss LSM 700). As a negative control, each staining included sections
stained without primary antibody.
4.6. Quantitative analysis of angiogenesis
For the analysis of retinal vasculature, eyes were enucleated, ﬁxed
with 4% PFA and retinas dissected. Flat mount retinas were blocked in
10% normal goat serum for 2 h, incubated overnight with Isolectin GS-
IB4 (1:200, Invitrogen, Carlsbad, CA) Retinas were imaged via confocal
microscope (Carl Zeiss LSM 700) and the rate of angiogenesis was de-
termined during development (P6) and in the OIR model as previously
described (Connor et al., 2009; Stahl et al., 2010b). Brieﬂy, retinas were
imaged using confocal microscopy (Carl Zeiss LSM 700) with 10 × ob-
jective by focusing on the preretinal neovascular tufts and the under-
lying superﬁcial vascular plexus. Areas of vascular obliteration and
pathological neovascularization (neovascular tufts) were computed, in
pixels, and divided by the total retinal area using Adobe Photoshop
CS3. The rate of developmental angiogenesis at P6 was determined by
measuring the diameter of vasculature via the optic nerve to the tips of
the blood vessels. Analysis of vessel branching and number of ﬁlopodia
sprouts were quantiﬁed as previously described (Lobov et al., 2007).
Each point where three capillary segments met was counted as one
junction. Branch points from the capillary plexus from two areas
(370 μm × 550 μm) per retina were counted and results are shown by
the average count per unit area. The number of ﬁlopodia protrusions
from the tip cells were counted from the length of 500 μm of the
sprouting vascular front (two measures per retina).
4.7. Statistical analysis
Student's t-test was conducted for normally distributed data and
nonparametric Mann-Whitney U test (GraphPad Prism 6.01 and IBM
SPSS statistics) for non-normally distributed data to test the statistical
signiﬁcance of the results. P-values less than 0.05 were considered
statistically signiﬁcant.
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PURPOSE. Oxygen-induced retinopathy (OIR) is the most widely used model for ischemic
retinopathies such as retinopathy of prematurity (ROP), proliferative diabetic retinopathy
(PDR), and retinal vein occlusion (RVO). The purpose of this study was to perform the most
comprehensive characterization of OIR by a recently developed technique, sequential
window acquisition of all theoretical mass spectra (SWATH-MS) proteomics.
METHODS. Control and OIR retina samples collected from various time points were subjected
to SWATH-MS and detailed data analysis. Immunohistochemistry from mouse retinas as well as
neovascular membranes from human PDR and RVO patients were used for the detection of
the localization of the proteins showing altered expression in the retina and to address their
relevance to human ischemic retinopathies.
RESULTS. We report the most extensive proteomic proﬁling of OIR to date by quantifying
almost 3000 unique proteins and their expression differences between control and OIR
retinas. Crystallins were the most prominent proteins induced by hypoxia in the retina, while
angiogenesis related proteins such as Filamin A and nonmuscle myosin IIA stand out at the
peak of angiogenesis. Majority of the changes in protein expression return to normal at P42,
but there is evidence to suggest that proteins involved in neurotransmission remain at
reduced level.
CONCLUSIONS. The results reveal new potential therapeutic targets to address hypoxia-induced
pathological angiogenesis taking place in number of retinal diseases. The extensive proteomic
proﬁling combined with pathway analysis also identiﬁes novel molecular networks that could
contribute to the pathogenesis of retinal diseases.
Keywords: proteomics, mass spectrometry, oxygen induced retinopathy, angiogenesis,
hypoxia
Retinal ischemic diseases, such as retinopathy of prematurity(ROP), diabetic retinopathy (DR), and retinal vein occlu-
sion (RVO) are major causes of visual impairment and blindness
in industrialized countries.1–5 The most prominent pathological
features of these diseases are abnormal angiogenesis and
enhanced vascular permeability, which leads to vision loss.
However, inﬂammation, oxidative stress, and neuronal dysfunc-
tion are also contributing to the pathogenesis of ischemic
retinal diseases.
The mouse oxygen-induced retinopathy (OIR) model6 is a
well-established animal model of ROP, which shares many
hallmarks with human proliferative diabetic retinopathy (PDR)
as well as neovascular RVO. Thus, it is the most widely used
model to study retinal ischemic diseases.7 OIR is characterized
by hyperoxia-induced vessel loss from retina followed by
regrowth of vasculature and formation of preretinal neovascu-
larization upon return to normoxia. It is considered mainly as
an angiogenesis model, but neuronal damage and pathological
effects on retinal glia have also been reported in OIR.8
Due to complex interactions between vascular, neuronal,
glial, and immune cells in retinal vascular disorders, it is
important to study changes in whole retinal tissue simulta-
neously to gain more information about the pathogenesis of
retinal disease. Mass spectrometry (MS)-based proteomic
proﬁling has become a widely-used approach to assess the
development and the progression of diseases.9 Full proteome-
based approach provides an unbiased method to study changes
in proteins involved in any given tissue, organ, or disease. As
the OIR model is considered as the most representative model
for a large number of neovascular human retinal diseases, there
has been considerable interest to characterize OIR with MS-
based approaches. Previous studies on rodent OIR proteome
have been done with Isobaric Tags for Relative and Absolute
Quantitation (iTRAQ) MS approach,10,11 and with ion-current-
based MS1 quantiﬁcation approach (ICB) from rat retinas.12
With these methods, it has been possible to quantify almost
30010,11 and 1300 proteins from retinas,12 respectively. In this
study, a recently developed technique,13 sequential window
acquisition of all theoretical mass spectra (SWATH)-MS proteo-
mics, was used to compare proteomes of mouse OIR model
with control retina. SWATH-MS is an MS method that combines
data-independent acquisition (DIA) and data-dependent acqui-
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sition (DDA), which iTRAQ and targeted data analysis uses,
extending the throughput of proteins and data completeness.14
Here we report the most extensive proteomic proﬁling of OIR
to date by relatively quantifying almost 3000 unique proteins.
The novel methodology used in the present study also allowed
the temporal proﬁling of OIR proteome for the ﬁrst time, while
in the previous studies, it has been possible to compare the
protein levels in a single time point. Immunohistochemistry
was used to study the localization of differently expressed
proteins in control and OIR retinas, as well as in neovascular
membranes obtained from PDR and RVO patients to address




WT C57BL/6 mice were used for the study. Mice were housed
under standard conditions with 12-hour dark/12-hour light
cycle and fed with standard laboratory pellets and water ad
libitum. The OIR model was generated as described in detail
previously.6,15–17 Brieﬂy, to induce OIR, the pups at postnatal
day 7 (P7) and their nursing mothers were exposed to 75%
oxygen (ProOx P110 oxygen controller; Biospherix Ltd.,
Parish, NY, USA) for 5 days until P12 when they were returned
to normal room air. Mice were sacriﬁced and retinas collected
at P13 (early hypoxic phase), at P17 (late hypoxic phase and
the peak of neovascularization), and at P42 (after vascular
recovery) to assess the effect of OIR on retinal proteome.
Control animals were housed under normal room air condi-
tions and retinas were harvested at corresponding days. The
study design is illustrated in Figure 1. As postnatal weight gain
has been shown to affect outcome in the OIR model,7 only the
pups weighing between 6.3 and 7.5 g at P17 were included in
the study. All animal experiments were conducted under ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research guidelines in accordance with protocols approved by
the National Animal Ethics Committee of Finland.
For the proteomic analysis, eye balls were harvested into
cold PBS and retinas were dissected immediately under the
dissection microscope, and retinas were snap frozen with
liquid nitrogen. Samples were stored in 708C until sample
preparation.
Proteomics
Chemicals and Materials. Acetonitrile (ACN), formic acid
(FA), water (UHPLC-MS grade), triethylammonium bicarbonate
buffer 1M (TEAB), sodium dodecyl sulfate (SDS), iodoaceta-
mide (IAA), triﬂuoroacetic acid (TFA), ammonium bicarbonate
(ABC), and urea were all purchased from Sigma Aldrich Corp.
(St. Louis, MO, USA). Radioimmunoprecipitation assay (RIPA)
cell lysis buffer, a cocktail (Halt Protease Inhibitor Cocktail),
and sample clean up tips (C18) were from Thermo Fisher
Scientiﬁc (San Jose, CA, USA). A kit (Bio-Rad DC) and bovine
serum albumin standard were purchased from Bio-Rad
(Hercules, CA, USA), and 30 kDa molecular weight cut off
(MWCO) centrifugal devices were from PALL (Port Washing-
ton, NY, USA).
FIGURE 1. Outline of the study. OIR was generated by exposing the mice pups for 75% oxygen for 5 days from P7 to P12. Control and OIR retinas
were collected to SWATH-MS analysis, while some retinas from each litter were used for histological examination to conﬁrm the changes in the
vasculature in OIR. Retinal vasculature was stained with Isolectin GS-IB4. OIR samples were collected during hypoxia at P13 when central retina is
avascular, at P17 when retina is partially revascularized and the neovascularization (preretinal tufts) peaks, and at P42 when retina is completely
revascularized and neovascularization is regressed. Age-matching control samples were collected from mice housed in normal room air. P13 n¼ 5;
P17 n ¼ 9; P42 n ¼ 6; P13 OIR n¼ 5; P17 OIR n¼ 6; P42 OIR n ¼ 7.
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Sample Preparation and Analysis. Proteins were ex-
tracted by submerging tissues to 300 lL RIPA cell lysis buffer in
ice and homogenized using plastic pestles and centrifuged
(2400g/min, 5 minutes). After centrifugation, tissue samples
were set in cold ultrasonic bath for 5 minutes and incubated on
ice for 25 minutes. After incubation, samples were centrifuged
at 21,000g for 20 minutes and the supernatant containing the
proteins were transferred to new tube. Protein concentration
was measured using Bio-Rad DC protein quantiﬁcation kit.
Average amount of protein recovered per sample was 253.8 6
32.9 lg (6 SD). Fifty micrograms of total protein was taken
from each sample to tryptic digestion.
Samples were then subjected to reduction, alkylation, and
tryptic digestion. These steps were performed as described in
detail in the Supplementary Methods. For MS analysis, the
samples were eluted to the same concentration and 4 lg
sample was injected into NanoLC-TripleTOF (Sciex 5600þ).
Two replicate MS analyses were produced from each sample.
Analysis of the samples was done by NanoLC-TripleTOF MS
using SWATH acquisition as described in the Supplementary
Methods.
Protein Identiﬁcation and Quantiﬁcation. As part of
the SWATH analysis method, a relative protein quantiﬁcation
library, consisting of >3500 retinal proteins, was created using
retina samples from this study. Overall library consisted of 32
different samples and 45 data-dependent analysis (DDA) runs
with same LC gradient and instrument settings that were used
for SWATH analyses. Library was created using Protein Pilot 4.7
(Sciex, Redwood City, CA, USA) and all DDA runs spectra were
identiﬁed against Mouse UniprotKB/SwissProt protein library.
Quantiﬁcation was done by Peak Viewer and Marker Viewer
(Sciex). False discovery rate (FDR) 1% was used in the library
creation and only distinctive peptides were used in the
quantiﬁcation. Retention time calibration was done for all
samples using 15 representative peptides from two different
proteins, a-enolase (ENO1) and albumin (ALB). Five transitions
per peptide and 1 to 15 peptides were used for protein
quantiﬁcation calculations. All statistically signiﬁcant (adjusted
P < 0.05) and other interesting proteins discussed further were
subjected to manual inspection of peptides. This consisted of
checking correct peak selection in the chromatogram (FDR 1%,
99% peptide conﬁdence level), sufﬁcient signal to noise ratio
inspection (>7), and chromatogram inspection in relation to
library chromatogram. Also, variation of replicate MS analysis
results was calculated as means to all samples/protein. All
peptides were eliminated from results processing if manual
inspection requirements were not fulﬁlled. Proteins with
missing values were excluded from consideration. Checked
proteins whose quantiﬁcation was based on only one speciﬁc
peptide are marked with †-symbol to the graphs and tables.
Most of these proteins were small proteins, meaning a small
likelihood of having more than one speciﬁc peptide identiﬁed
for quantiﬁcation.
Western Blotting. Retinal protein lysates were run into
SDS PAGE gels, transferred to polyvinylidene diﬂouride (PVDF)
membranes, and immunoblotted with anti-Flna, anti-Myh9, and
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) anti-
bodies, as described in the Supplementary Methods.
Immunohistochemistry. For the retinal ﬂat mount
analysis, the eye balls were harvested at P13, P17, and P42.
Eye balls were ﬁxed with 4% paraformaldehyde (PFA) for 1
hour where after retinas were dissected, stained with isolectin
(Isolectin GS-IB4; Invitrogen, Carlsbad, CA, USA), ﬂat mounted,
and imaged via confocal microscope (LSM 700; Carl Zeiss,
Oberkochen, Germany).
For immunohistochemistry, the eye balls were harvested,
ﬁxed with 4% PFA for 4 hours, and processed for parafﬁn
embedding. Five-micrometer thick sections were subjected to
antigen retrieval (Tris-EDTA, pH9), blocked and incubated
either with anti-Filamin-A antibody (Cat#ab76289; Abcam,
Cambridge, UK) or anti-Myh9 antibody (Cat#11128-1-AP;
Proteintech, Rosemont, IL, USA) followed by horseradish
peroxidase (HRP) conjugated secondary antibodies. For
immunoﬂuorescence (IF) double-staining, sections were pre-
treated with trypsin and incubated with anti-Myh9 antibody
(Proteintech) and anti-CD31 (Cat#550274; BD BioSciences, San
Jose, CA, USA) or anti-Myh9 and anti-NG2 (provided by W.
Stallcup, Sanford Burnham Prebys Medical Discovery Institute,
La Jolla, CA, USA),18 followed by appropriate Alexa Fluor dye
conjugated secondary antibodies (Invitrogen). Samples were
imaged via confocal microscope (LSM700; Carl Zeiss).
Neovascular membranes were obtained from nine PDR and
one RVO patients, who were undergoing pars plana vitrecto-
my. At the time of surgery, patients’ mean age was 37 years
(range, 27–56 years) and mean duration of diabetes was 26
years (range, 21–32 years). The protocol for collecting human
tissue samples was approved by the institutional review boards
of the Pirkanmaa Hospital District, and the study was
conducted in accordance with the Declaration of Helsinki.
All patients gave written informed consent. The ﬁbrovascular
membranes were isolated, grasped with vitreous forceps, and
pulled out through a sclerotomy. Samples were immediately
ﬁxed with 10% formalin for 3 hours, transferred to 70%
ethanol, and processed for parafﬁn embedding and immuno-
histochemistry. Samples were stained with anti-Myh9 antibody
(Proteintech) and anti-HSA (cat #LS-B6178; LSBio, Seattle, WA,
USA) followed by HRP conjugated secondary antibodies.
Statistical Analysis. Proteins were quantiﬁed and log2-
transformation was applied to the data, and in addition,
geometric means of replicate MS analyses were taken. No
further normalization was deemed necessary. The quality of
the replicate MS analyses was analyzed by analyzing the
intraclass correlation (ICC), and Spearman’s rank correlation
was used to generate P values in permutation tests (n ¼ 1000
permutations / replicate MS analyses).
Principal component analysis (PCA) was used to cluster the
samples based on full proteomic proﬁles. Two-sample t-test
was used to analyze differences between the relative protein
expression levels of control and OIR retinas. Levene’s test was
performed for the statistically signiﬁcant proteins (after P value
adjustment), and two proteins had a P value < 0.05. For these
proteins, the statistical signiﬁcance was checked with Wilcox-
on rank sum test.
Benjamini-Hochberg adjustment was used to account for
multiple testing, and the signiﬁcance threshold, a, was set at
0.05. All statistical analyses for the proteomics data were
performed using R software version 3.2.3 (R Core Team,
Foundation for Statistical Computing, Vienna, Austria) and IPA
software (IPA; QIAGEN, Redwood City, CA, USA).
RESULTS
Protein Proﬁles Are Associated With the
Developmental Stage of the Retina
To study the protein proﬁles of control and OIR retinas, we
ﬁrst conﬁrmed the development of OIR by staining the
vasculature from retinal ﬂat mounts at different time points
(Fig. 1). With SWATH-MS quantiﬁcation, we then used a library
of 121,145 peptides from 32 samples, corresponding to
1,576,233 identiﬁed spectra in an assembly of 3316 protein
groups using FDR of 1.0%. From this library, 2944 proteins had
distinct peptides sequences with matching spectra to SWATH-
MS analysis, and these proteins were quantiﬁed in all samples.
Out of 2944 relatively quantiﬁed proteins, the quantiﬁcation
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was based on more than one peptide in 2177 proteins. Proteins
quantiﬁed using a single peptide are marked in the ﬁgure
legends. The replicate MS analysis quality checks showed that
the ICC coefﬁcient was 0.99 between the replicates. Permu-
tation tests using Spearman’s correlation showed that 94.4% of
the replicate MS analyses had a P < 0.05, which suggests that
they were of excellent quality.
For the proteomic data, we ﬁrst wanted to evaluate the
underlying patterns and differences between time points. PCA
was performed for the whole data, and the plotting results
based on the ﬁrst two components suggested that there was a
clear division between different time points of both control
and OIR retina samples (Fig. 2). In addition, some separation
was seen between control and OIR retinas at P13 and P17. At
P42, the two groups were overlapping and there was no longer
detectable division between control and OIR protein proﬁles.
Taken together, the strongest cause for the differences in
protein expression levels based on the ﬁrst component
appears to be the developmental stage of mouse retina.
Differential Expression Analysis of OIR and
Control Retinas: The Induction of Crystallins by
Hypoxia at P13 and Angiogenesis-Related Proteins
at P17
Next, we performed differential expression analysis in order to
identify proteins, which differed between control and OIR
samples in speciﬁc time points. Comparison of control and OIR
samples resulted in 364 differentially expressed proteins at
P13, 387 at P17, and 104 at P42 (P < 0.05) prior to further P
value adjustments. These proteins are listed in Supplementary
Table S1 for P13, Supplementary Table S2 for P17, and
Supplementary Table S3 for P42.
P value adjustments to account for the multiple hypotheses
testing reduced the number of statistically signiﬁcant results
and led to 17 differentially expressed proteins at P13, 22 at
P17, and none at P42. To visualize the differential expression in
response to hypoxia at P13, P17, and P42, volcano plots are
shown (Figs. 3A–C). In addition to visualizing the statistically
signiﬁcant (adjusted P < 0.05) proteins and their associated up-
or downregulation, the plots revealed a highly upregulated
group of proteins in response to hypoxia at P13 OIR (Fig. 3A).
These proteins are crystallins, including members of a-, b-, and
c-crystallins. The expression levels of individual crystallins did
not reach statistically signiﬁcant difference after P value
adjustment, but they are the most upregulated proteins in
the whole data according to fold change (FC) (log2 FC 2.67–
4.32) (Supplementary Fig. S1 and Supplementary Table S1). It
is also noteworthy that based on FC alone, the most
upregulated (log2 FC > 2) proteins at the peak of the
FIGURE 2. PCA shows distinct clustering of retinal proteins based on
the developmental stage of the retina. The protein proﬁles obtained
from control and OIR retinas are clearly different at P13 (red), P17
(green), and P42 (blue). Control () and OIR (m) samples are also
separated quite distinctively within the clusters at P13 and P17, but no
more at P42.
FIGURE 3. Volcano plots of the differential expression analysis. The log2 FC is displayed in the x-axis and the P value (log10) is shown in the y-axis
and hence, proteins in the top right and left corners are the most interesting ones as they represent the most heavily upregulated or downregulated
proteins in OIR. Points with darker gray are proteins with an adjusted P value < 0.05. (A) At P13, there were 17 proteins with adjusted P < 0.05
and these were all downregulated in OIR samples. The blue cluster (A) shows the crystallins, which were noticeably upregulated although most
members of the crystallin family did not reach threshold for statistical signiﬁcance. (B) Altogether 22 proteins showed differential expression based
on their adjusted P < 0.05 in OIR at P17. In general, more proteins were upregulated in OIR samples compared to control retinas at P17 than at
other studied time points. (C) One protein (Cartpt) was deemed statistically signiﬁcant (based on the adjusted P value) at P42, but was discarded
from the results during the manual peak evaluation.
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angiogenesis (at P17), were vitamin D-binding protein (Gc), a-
2-HS-glycoprotein/fetuin-A (Ahsg), a-1-antitrypsin 1-4 (Serpi-
na1d), and carboxylesterase 1C (Ces1c) (nonadjusted P <
0.05) (Supplementary Table S2). Of the aforementioned
proteins, one (Ahsg) was also statistically signiﬁcant (Fig. 3B).
At P42, cocaine- and amphetamine-regulated transcript protein
(Cartpt) was initially found to be statistically signiﬁcant after
the P value adjustment (Fig. 3C). However, this change was
deemed unreliable after manual peak checking.
The heat maps of the statistically signiﬁcant results at P13
and P17 show the relative expression of the proteins and the
differences between control and OIR samples (Figs. 4A, 4B).
Four proteins had statistically signiﬁcant difference at P13
(absolute log2 FC > 0.585; i.e., FC above 1.5: abs(log2(1.5)):
glutamine synthetase (Glul), guanylyl cyclase GC-E (Gucy2e),
cGMP-gated cation channel a-1 (Cnga1) and rod outer segment
membrane protein 1 (Rom1) (Fig. 4). Substantially more
proteins showed similar difference (log2 FC > abs(log2(1.5))
in the expression levels between OIR and control at P17: Ahsg,
annexin A2 (Anxa2), transgelin-2 (Tagln2), cell surface
glycoprotein MUC18 (Mcam), tropomyosin a-4 chain (Tpm4),
ﬁlamin-B (Flnb), protein SON (Son), Gpx1, vinculin (Vcl),
myosin-9 (Myh9), serpin H1 (Serpinh1), ﬁlamin-A (Flna),
moesin (Msn), and annexin A6 (Anxa6) (Figs. 4B, 5). Similarly,
downregulated proteins at P17 OIR were Glul, prosaposin
receptor GPR37 (Gpr37), sideroﬂexin-5 (Sfxn5), and synaptic
vesicle glycoprotein 2A (Sv2a) (Fig. 4B). Signiﬁcantly down-
regulated proteins both at P13 OIR and P17 OIR were Glul and
retinaldehyde-binding protein-1 (Rlbp1). The mean expression
values are illustrated in Figure 5 and in Supplementary Figure
S2 for all of the statistical signiﬁcant proteins (adjusted P value
< 0.05). There were no proteins with altered expression level
at P42 OIR after P value adjustment.
Hypoxia Induces Filamin-A Cleavage at P17 OIR
In order to validate the results from proteomic analysis of
OIR, Flna and Myh9 were selected for immunoblotting.
Immunoblotting with C-terminal anti-Flna antibody con-
ﬁrmed increased Flna expression at P17 OIR (4.6-fold
compared to P17 control). In hypoxia, Flna is cleaved by
calpain-proteases to generate 90 kDa C-terminal fragment
that interacts with hypoxia-inducible factor-1a (HIF-1a) and
promotes angiogenesis.43 The expression of C-terminal
fragment of Flna (FlnaCT) generated in the presence of
hypoxia was increased 14-fold in OIR at P17 OIR (Figs. 5C,
5D). Next, the expression of Myh9 was studied in OIR by
immunoblotting. A 9.6-fold increase in the expression of the
Myh9 was seen at P17 OIR when compared to the expression
at P17 controls (Figs. 5E, 5F).
Filamin-A and Myh9 Expression Is Increased in the
Angiogenic Blood Vessels in OIR Retinas
While proteomic analysis and immunoblotting revealed an
increased expression of Flna and Myh9 at P17 OIR, immuno-
histochemical stainings conﬁrmed substantially stronger ex-
pression of these proteins from P17 OIR retinas than from
control retinas (Fig. 5G). We observed marked increase in Flna
expression in preretinal tufts and blood vessels of inner retina
in the OIR retinas in comparison to controls. Also, a faint
staining is seen in others cell types, presumably retinal
neurons, but the expression level in neurons looks identical
in control and OIR retinas. Thus, the induction of Flna
expression seen in OIR at P17 is clearly from the angiogenic
blood vessels.
Myh9 expression in OIR retinas was studied in detail by
performing double-immunoﬂuorescent stainings for Myh9 and
endothelial cell (CD31), and pericyte (NG2) markers. Strong
Myh9 expression was localized to endothelial cells and
pericytes in OIR at the peak of the angiogenesis at P17. All
endothelial cells expressed Myh9, while there were some
pericytes negative for Myh9 at P17 OIR (Fig. 6).
Abundant Expression of Myh9 on Neovascular
Membranes From Human PDR Patients
Generally, the expression levels of Myh9 reﬂect the overall
stiffness of the tissue.19–21 The increased matrix stiffness
destabilizing endothelial cell–cell junctions impairs the
endothelial barrier function and leads to enhanced endothe-
lial permeability.22 We next studied Myh9 and human serum
albumin (HSA; i.e., marker of vascular leakage) expression on
human ﬁbrovascular membranes (using adjacent tissue
sections) from vitrectomized patients with PDR and RVO.
Strong ﬁbrosis formation leads to retinal traction and
ultimately to retinal detachment in RVO. The samples
represent the end stage of these diseases, where substantial
amount of ﬁbrosis has been formed, but the samples still
contain also regions with active pathologic angiogenesis.
When only a faint expression of Myh9 is seen outside of the
blood vessels, the intensity of Myh9 staining in blood vessels
is also faint one (Fig. 7). Strong Myh9 expression was seen
both in the blood vessels and in the matrix in some samples
and then HSA starts to accumulate in the tissue. Particularly
strong Myh9 expression was seen all over the ﬁbrotic
membrane in the RVO sample that contains blood vessels
and massive scarring (Fig. 7). Comparison of Myh9 expression
to HSA expression showed a strong positive correlation
between the two; more Myh9 expressing cells (increased
matrix stiffness) outside the blood vessels, more Myh9
expression (contractility and destabilization of cell–cell
junctions) in the blood vessels and the more abundant
vascular leakage outside the blood vessels (Fig. 7).
Ingenuity Pathway Analysis (IPA) Identiﬁes Angio-
genesis and Transforming Growth Factor-b1 (TGF-b1)
Pathway As the Most Prominent Features of OIR at P17.
In order to connect the differentially expressed proteins to
speciﬁc pathways and biological functions, pathway analysis
was performed using IPA on the proteins showing statisti-
cally signiﬁcant differences in their expression between
control and OIR retinas (adjusted P < 0.05) in each time
point. The top canonical pathways connected to the 17
proteins at P13 (Fig. 4A) were phototransduction pathway (P
¼ 4.95e-10) (Supplementary Fig. S3), protein kinase A
signaling (P ¼ 2.29e-04), and glutamine biosynthesis I (P ¼
8.05e-04). There were no unbiased activation scores <2 or
> 2 for disease and biological functions or for upstream
regulators.
For the 22 proteins identiﬁed in differential expression
analysis at P17 (Fig. 4B), the top canonical pathways were actin
cytoskeleton signaling (activation score ¼ 2.1, P ¼ 3.18e-06),
ILK signaling (activation score ¼ 1, P ¼ 4.61e-05), and
glutamine biosynthesis I (P ¼ 1.04e-03). We then performed
the disease and biological function enrichments analyses,
which showed both necrosis and cell death reduced (P ¼
7.25e-04 and P ¼ 6.94e-05, both with activation score  2),
while angiogenesis was increased (P ¼ 2.53e-04, activation
score ‡ 2). According to IPA, the increase in angiogenesis was
due to the upregulation of Anxa2, Flna, Flnb, Gpx1, Mcam,
Myh9, and Serpinh1. For further classiﬁcation, upregulated
proteins Tagln2, Vcl, Mcam, Flnb, ATP-dependent 6-phospho-
fructokinase (Pfkp), Myh9, and Flna are proteins involved in
cell–cell adhesion (Amigo2). In addition, the upstream
regulator analysis identiﬁed TGF-b1 (Tgfb1), MAP kinase-
interacting serine/threonine-protein kinase 1 (Mknk1), and
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MKL/myocardin-like protein 2 (Mkl2) as potential upregulated
enhancers of angiogenesis (for all P < 0.001 and activation
score ‡ 2), while brain-derived neurotrophic factor (Bdnf),
Krueppel-like factor 3 (Klf3), and Myc proto-oncogene protein
(Myc) were inhibited (for all P < 0.001 and activation score 
2) (Supplementary Table S4).
Marginal Long-Term Changes in the Protein
Expression Persist in OIR Retina
There were no proteins with statistically signiﬁcant difference
in the expression levels between OIR and control retina after P
value adjustment at P42. We then performed the IPA analysis
FIGURE 4. Heat maps of differentially expressed proteins between control and OIR retinas. Retinas from control and OIR mice were harvested at
P13, P17, and P42 and processed to MS-SWATH analysis. The colors display discretized values of the relative protein expression levels as described
in the color key legend. (A) Seventeen proteins downregulated during hypoxia at P13 OIR retinas compared to control retinas at P13 (adjusted P
value < 0.05). (B) Twenty-two proteins up- or downregulated at P17 (neovascularization) OIR compared to control retinas at P17 (adjusted P value
< 0.05). † ¼ protein quantiﬁcation based on only one speciﬁc peptide. ‡ ¼ proteins that had signiﬁcant Levene’s test results (P value < 0.05),
suggesting potential issues with t-test assumptions. For these proteins, the statistical signiﬁcance was checked also with Wilcoxon rank sum test and
results were deemed statistically signiﬁcant.
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FIGURE 5. Differentially expressed proteins in OIR during hypoxia and angiogenesis. Mice pups were exposed to hyperoxia-induced OIR, and
retinas were harvested at P13, P17, and P42. All retina samples were analyzed by MS-SWATH and the data underwent statistical analysis to compare
control and OIR samples in each time point. The means and standard error bars are shown for control (red) and OIR (blue) samples for chosen
proteins during hypoxia at P13 (A) and at the peak of neovascularization at P17 (B). The asterisks identify statistically signiﬁcant differences
between the two groups before P value adjustment (*), and after P value (**) adjustment. Note that Glul (A) is different both at P13 and at P17. (C)
Western blot membrane immunoblotted with anti-Flna antibody shows increased Flna expression at P17 OIR and hypoxia-induced cleavage of C-
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for proteins with nonadjusted P value (P < 0.05) as statistically
signiﬁcant (Supplementary Table S3). IPA analysis revealed
decreased neurotransmission (P¼ 6.56E-05, activation score¼
2) at P42 OIR compared to control retinas as the only
signiﬁcant difference between the groups. Altogether, 11
proteins in neurotransmission were involved (Supplementary
Fig. S4A) and further examination revealed changes in the
synaptic vesicle cycle pathway (KEGG) (Supplementary Fig.
S4B). Selection of proteins upregulated at P42 OIR are
illustrated in Figure 8. These are proteins associated at least
with cell migration and adhesion, and retinal glial cells (Fig. 8).
DISCUSSION
We have carried out the most comprehensive proteomics
analysis of the commonly used experimental retinal angiogen-
esis model, OIR. The results reveal that in addition to the
changes detected on proteins responding to hypoxia and those
regulating angiogenesis, some changes in protein expression
take place in the neuronal tissue of the retina. This is in
accordance with the fact that human retinal vascular diseases
are associated with neuropathy and gliopathy. Furthermore,
the dysregulation of the cross talk between vasculature and
retinal neuroglia and neuronal cells has been shown to
contribute to the pathogenesis of DR.23–25
During the hypoxic phase, the most upregulated proteins
were crystallins, which are small heat shock proteins that act
as molecular chaperones by binding misfolded proteins to
prevent their denaturation and aggregation.26,27 They protect
cells from hypoxia and maintain mitochondrial integrity.26,28 In
addition to their neuroprotective role, crystallins also have
other roles in vascular biology.29,30 aB-crystallin functions as a
chaperone for VEGFA and is crucial for its proper secretion,
which in turn, is crucial for endothelial cell survival in
hypoxia.28,31,32 Thus, aB-crystallin knockout mice had less
VEGFA and neovascularization than WT in OIR.31 In the eye,
crystallins were originally characterized as abundant lens
proteins, but they are also expressed in developing and mature
retina.28,32–34 Their expression is dramatically upregulated in
numerous retinal diseases, such as mechanical injury, ischemic
insults, age-related macular degeneration (AMD), uveoretinitis,
and DR.28 Concerning the potential therapeutic value of
crystallins in retinal diseases, their exact functions are
emerging.27,35 Namely, the recently discovered roles for aB–
crystallin in mediating TGF-b induced epithelial-mesenchymal
transformation (EMT) and subretinal ﬁbrosis in AMD,27 while
aA–crystallin providing neuroprotection for retina in DR,35
point out the opposite therapeutic values for these crystallin-
family members.27,36
A large number of proteins was also downregulated in
response to hypoxia in retina. Among these proteins were
Cnga1, Gucy2e, Rom1, and Grk1, proteins associated with
phototransduction. Since rod photoreceptors are the most
oxygen-dependent cells in the retina,37 the downregulation of
proteins associated with rod function is a plausible outcome in
hypoxia.
FIGURE 6. Myh9 is expressed in retinal blood vessels and induced by angiogenesis during OIR. (A) Control and OIR retinas were processed for IHC
and stained for nonmuscle myosin IIA (Myh9) as described in the Materials and Methods section. Myh9 expression is conﬁned to blood vessels in
normal retina at P17. Strong Myh9 is induced in the angiogenic blood vessels at the peak of angiogenesis in OIR retina at P17. (B) Double-IF stainings
for Myh9 and endothelial cells (CD31) (B) and Myh9 and pericytes (NG2) (C) conﬁrmed that the Myh9 expression comes from endothelial cells and
from some of the pericytes in OIR retina at P17. Arrows (C) are pointing to pericytes that do not express Myh9. GCL, ganglion cell layer; IPL, inner
plexiform layer; INL, inner nuclear layer, OPL, outer plexiform layer; ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segments. Scale
bars represent 50 lm in panel A and 20 lm in panels B and C.
terminal fragment of Flna (FlnaCT). (D) Densitometric quantiﬁcation revealed 4.6-fold induction in total Flna protein levels, while FlnaCT levels were
increased 14-fold at P17 OIR compared to P17 control samples. (E, F) Western blotting against Myh9 and densitometric quantiﬁcation showed 9.6-
fold induction at P17 OIR compared to P17 control samples. (*P < 0.05; **P < 0.01; ***P < 0.001) (G) Control and OIR retinas collected at P17 were
processed for immunohistochemical analysis and stained for Flna and Myh9 as described in the Materials and Methods section. Both Flna and Myh9
expression is increased in OIR retinas compared to controls. Strong expression of Flna and Myh9 can be seen from preretinal tufts (arrows) and
from the blood vessels in inner retina in OIR. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer, OPL, outer plexiform
layer; ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segments; RPE, retinal pigment epithelium. Scale bars represent 200 lm. † ¼
protein quantiﬁcation based on only one speciﬁc peptide. ‡¼ statistical signiﬁcance was checked also with Wilcoxon rank sum test due to positive
Levene’s test results.
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The most abundant changes in the retinal protein expres-
sion in OIR were seen at the peak of neovascularization at P17.
Among the most upregulated proteins were plasma proteins
Ahsg, Gc, Apoa1, Alb, and Tf (Supplementary Table S2). This is
most probably due to increased permeability of the angiogenic
blood vessels, which leads to the accumulation of plasma
proteins in retinal tissue by leakage. However, some of these
proteins could also have relevant biological functions, not just
be bystanders by leakage, in OIR. Fetuin-A (Ahsg) as well as its
cellular receptors, Anxa2 and -6, were highly upregulated in
OIR. Fetuin-A is an adhesive glycoprotein that binds to Anxa2
and -6 and induces cell proliferation in its target cells.38 Anxa2,
in turn, drives angiogenesis in OIR.38 Gc is a multifunctional
glycoprotein that acts as a carrier protein for vitamin D but can
also modulate certain immune and inﬂammatory responses.39
Vitamin D, in turn, is known to inhibit retinal neovasculariza-
tion in OIR,40 and vitamin D receptor agonists inhibit
developmental retinal angiogenesis.41 Thus, the accumulation
of Gc by the leakage from the angiogenic blood vessels could
be a natural, endogenous signal to suppress angiogenesis at the
time angiogenesis reaches its peak in OIR.
In line with the extensive angiogenesis taking place in
retina at P17, IPA analysis revealed proteins ‘‘related to
angiogenesis’’ being the most signiﬁcantly upregulated pro-
teins. Among these proteins were Filamins, Flna and Flnb. In
hypoxia, oxygen-sensing prolyl hydroxylase domain protein 2
(PHD2) inactivation rapidly upregulates Flna expression.42
Flna, in turn, interacts physically with HIF-1a and promotes
angiogenesis.43 Hypoxia induces calpain-dependent cleavage
of Flna, and its C-terminal fragment (FlnaCT) accumulates in the
nucleus and facilitates the nuclear localization of HIF-1a.43 Our
study shows that hypoxia induces Flna cleavage, that is, FlnaCT
FIGURE 7. Myh9 is strongly expressed in human PDR and RVO ﬁbrovascular membranes. Adjacent sections of ﬁbrovascular membranes obtained
from pars plana vitrectomies from PDR and RVO patients were stained for blood vessels (CD31), Myh9, and HSA. (A) Rather faint Myh9 expression
was restricted to the blood vessels while almost no HSA accumulation was seen outside of the blood vessels in some PDR samples [PDR (i)]. Strong
Myh9 expression was seen not only in the blood vessels, but also in the cells outside of the blood vessels and HSA had accumulated into the
ﬁbrovascular membrane’s extracellular matrix in some PDR cases [PDR (ii)] as a sign of prominent vascular leakage. Especially strong Myh9
expression as well as substantial HSA accumulation were seen throughout the RVO sample, where strong ﬁbrosis formation has taken place. (B)
High magniﬁcation images from PDR patient (iii) show strong Myh9 expression in the highly vascularized area where HSA has leaked into the
extracellular matrix (arrows). Scale bars represent 200 lm in panel A and 100 lm in panel B. M, male; F, female.
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generation in OIR. Very recently it was shown that blocking
the calpain-dependent cleavage of Flna impairs tumor cell
proliferation and migration.44 Furthermore, it is worth noting
that Flna also interacts with small GTPase, R-Ras,45,46 the
master regulator of vascular permeability in angiogenesis46–50
and the gene needed for proper endothelial lumenogenesis.51
The interaction between Flna and R-Ras is crucial for
controlling vascular permeability in angiogenesis.45,46 R-Ras,
in turn, regulates vascular permeability in OIR and the reduced
expression of R-Ras is associated with vascular leakage in
PDR.16 The interaction between R-Ras and Flna takes place
with the N-terminal part of Flna.45 Thus, selective blocking of
the C-terminal cleavage of Flna (FlnaCT) could potentially be
therapeutic in ischemic retinal diseases with pathological
angiogenesis.
Another angiogenesis-related protein that stands out is
Myh9. Myh9 gene encodes for Myosin 9, a heavy chain of
Myosin IIA, a cytoskeletal contractile protein.52 In general, the
expression levels of Myh9 reﬂect the stiffness of the tissue;
cells in stiff tissues express plenty of Myh9, while the cells in
nonstiff tissues express low levels of Myh9.19–21 In addition to
the stiffness of the tissue, cell migration induces high
mechanical strains on the cells as their ‘‘pierce’’ through
extracellular matrix. Thus, the migrating cells upregulate the
expression of Myh9 to make themselves more rigid to
withstand the mechanical forces placed on them during the
migratory process,19–21 but their enhanced contractility
destabilizes endothelial cell–cell junctions and impairs endo-
thelial barrier function, resulting in increased vascular perme-
ability.22,53,54 Angiogenesis is essentially a cell migratory
process and as shown in this study, the upregulation of the
Myh9 takes place in the angiogenic endothelial cells in the
retina. Thus, the induction of Myh9 during the peak of
angiogenesis in OIR is plausible phenomenon, but could also
be highly relevant as the increased vascular leakage is a
hallmark in OIR. We also studied samples obtained from human
PDR and RVO patients and showed that the vascular leakage in
these diseases correlates with the amount of Myh9 expression
in this area. Endothelial cell contractility (i.e., enhanced Myh9
expression) increases not only with cell migration, but also
with the increased matrix stiffness resulting in increased
endothelial permeability due to impaired endothelial barrier
function.22,53–55 Thus, the changes in matrix stiffness and the
resultant endothelial cell contractility could be highly relevant
for large number of neovascular retinal diseases associated
with pathological leakage from the blood vessels.
Myh9 also regulates angiogenesis via controlling the
production of VEGFA in ischemia-driven arteriogenesis56 as
well as controlling nucleolin translocalization.57 Nucleolin is
primarily a nuclear protein that translocates to cell surface in
angiogenesis.57–59 The different antagonists of nucleolin,
among them Myh9 antibodies, have been shown to inhibit
tumor angiogenesis by stabilizing the pathological vascula-
ture,57,59 which enhances tissue oxygenation.59 The modest
increase (log2 FC 0.23) in nucleolin expression seen by MS in
OIR at P17 suggests that the effects of nucleolin in
angiogenesis is merely related to its translocation from nucleus
to cell surface than increase in its expression level.
The present proteomics approach quantiﬁes complete
expression pattern of almost 3000 proteins and thus provides
strong value to identify pathways involved in OIR. Using the
upstream regulator analysis with IPA, the most potential and
activated upstream regulator driving angiogenesis was TGF-b1.
This is in accordance with previous studies showing TGF-b1
upregulation in OIR.60 Interestingly, conditional ocular dele-
tions of TGF-b signaling results in pronounced structural
changes of retinal capillaries and a phenotype similar to human
DR.61,62 The upstream regulator analysis identiﬁed Mkl2 and
FIGURE 8. Selection of upregulated proteins at P42 OIR. Mice were exposed to OIR, and control and OIR retinas were harvested at P13, P17, and
P42. Samples were analyzed by MS-SWATH, and the data underwent statistical analysis to compare control and OIR samples. The means and
standard error bars are shown for control (red) and OIR (blue) samples for chosen proteins involved in cell migration and adhesion (Fgf2, Anxa5,
CD44) and retinal glial cells (Gfap). Rbp3 has a critical role in visual cycle. The asterisks identify statistically signiﬁcant differences between the two
groups before P value adjustment (P value < 0.05).
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Mknk1 as enhancers of angiogenesis in OIR. Mkl2, a
transcriptional coactivator, regulates conserved TGF-b signal-
ing pathway.63 Mice deﬁcient for Mkl2 die at the early
embryonic state, and Mkl2/ ECs have defects in cytoskeletal
organization and cell adhesion.63 Mkl2/TGF-b pathway is
required for the maturation and stabilization of embryonic
vasculature,63–65 but also for the myoﬁbroblast transformation
and EMT induction.66,67 The enhanced TGF-b signaling taking
place in vasculature leads to the endothelial-mesenchymal
transition (EndMT), a process that has many similarities with
EMT.68,69 The transformed endothelial cells have high vascular
permeability, further driving inﬂammation and by thus
perpetuating the incomplete repair state.69 This inﬂamma-
tion–TGF-b circuit in vasculature also promotes ﬁbrosis in the
surrounding tissue, and it is largely irreversible.68,69 The
recently identiﬁed association between TGF-b signaling and
ab-crystallin in the EMT and subretinal scarring,27 the massive
induction of crystallins by hypoxia and the subsequent
activation of TGF-b/Mkl2-signaling pathways in OIR provide
clues about the potential interplay that leads to retinal ﬁbrosis
in the human neovascular diseases of retina.
Another upstream regulator potentially enhancing angio-
genesis in OIR is Mknk1/MNK1. Mknk1 is a kinase that
exclusively phosphorylates a cap-binding subunit of the eIF4F
translation initiation complex, elF4E, and selectively facilitating
translation of proliferation, migration, and survival promoting
mRNAs, among them VEGFA.70 Inhibition of eIF4E phosphor-
ylation, in turn, suppressed angiogenesis.71 In retina, eIF4E
interacts with 4E-bp1, which expression is enhanced in retina
by diabetes-induced hyperglycemia and necessary for VEGFA
expression.72,73 Our results suggest that blocking MNK-eIF4E
pathway could be a potential target for blocking pathological
angiogenesis in retinal diseases.
We included the late OIR-time point, P42, in our study to
assess whether hypoxic exposure and subsequent neovascu-
larization cause permanent changes in the protein expression
in the retina. Very little is known about the long-term effects of
OIR on retina, although the information could be useful to
understand the prognosis of ROP. The disruption of the retinal
morphology as well as decrease in neuronal function have
been reported after OIR.74 Our IPA analysis revealed decreased
neurotransmission at P42 OIR retinas. Further examination
revealed changes in the synaptic vesicle cycle pathway (KEGG)
(Supplementary Fig. S4).
The present proteomics analysis revealed novel pathways
that might contribute to the development of pathological
angiogenesis in OIR. Furthermore, we were able to identify
molecular interplay between the proteins induced by hypoxia
and then by subsequent angiogenesis in OIR. They could be
potential druggable targets of retinal diseases inﬂected with
hypoxia and neovascularization.
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Supplementary method information 
Denaturation, alkylation, reduction and tryptic digestion 
Same protocol has been used before. 1 After the proteins were extracted from tissue samples and 
proteins concentration was measured 0.05 M ABC, denatured with 2 % SDS and reduced with 50 
mM Tris- (2-carboxyethyl) phosphine. After 60 min of incubation at + 60 °C samples were 
centrifuged and transferred into Pall Nanosep® 30 kDa MWCO centrifugal devices with low protein 
binding membrane and flushed two times with 200 Ol of 8 M urea solution followed by iodoacetamide 
alkylation for 20 min in dark at RT. Samples were flushed three times with 8 M urea solution and 50 
mM ABC before starting the enzymatic digestion with trypsin for 16 h at + 37 °C. Ratio of trypsin to 
protein in enzymatic digestion was 1:25. The following day samples were flushed twice with 40 Ol 
0.1M TEAB and once 50 Ol 0.5 M NaCl to collect peptides from the filter and dried in speed vacuum. 
Samples were solubilized to 0.1 % TFA and desalted with C18 tips. The tips were conditioned with 
50 % ACN and equilibrated with sample solvent. The clean-up was performed by aspirating and 
dispensing samples for 10 cycles. Tips were then rinsed with 2.5 % ACN in 0.1 % TFA. Finally, 
peptides were eluted with 80 % ACN in 0.1 % FA. Samples were dried in speed vacuum concentrator 
and stored at -20 °C until reconstituted to loading solution (5 % ACN, 0.1 % FA and HMR calibration 
peptides according to manufacturer guidelines) NanoRPLC-TripleTOF SWATH analysis. SWATH 
analysis samples were diluted to equal concentrations before injection to the instrument.  
NanoRPLC-TripleTOF 
Retinal proteins were analyzed by Nano-RPLC- TripleTOF instrumentation using Eksigent 425 
NanoLC FRXSOHGWRKLJKVSHHG7ULSOH72)PDVVVSHFWRPHWHU6FLH[&RQFRUG&DQDGD$
microcapillary RP-LC column (cHiPLC® ChromXP C18-CL, 3 Om particle size, 120 Å, 75 Om i.d 
× 15 cm, Eksigent Concord, Canada) was used for LC separation of peptides. Samples were first 
loaded into trap column (cHiPLC® ChromXP C18-CL, 3 Om particle size, 120 Å, 75 Om i.d × 5 mm) 
from autosampler and flushed for 10 min at 2 Ol/min (2 % ACN, 0.1 % FA). The flush system was 
then switched to line with analytical column. Tear samples were analyzed with 120 min 6 step 
gradient using eluent A: 0.1 % FA in 1 % ACN and eluent B: 0.1 % FA in ACN (eluent B from 5 % 
to 7 % over 2 min, 7 % to 24 % over 55 min, 24 % to 40 % over 29 min, 40 % to 60 % over 6 min, 
60 % to 90 % over 2 min and kept at 90 % for 15 min, 90 % to 5 % over 0.1 min and kept at 5 % for 
13 min) at 300 nl/min. 
Key parameters for TripleTOF mass spectrometer in SWATH ID library analysis were: ion spray 
voltage floating (ISVF) 2300 V, curtain gas (CUR) 30, interface heater temperature (IHT) +125°C, 
ion source gas 1 13, declustering potential (DP) 100 V. Library for SWATH analysis was created 
from the same samples by information dependent-aquisition (IDA) method and relative quantitation 
analysis was done by SWATH method. All methods were run by Analyst TF 1.5 software (Sciex, 
Redwood City, USA). For IDA parameters, 0.25 s MS survey scan in the mass range 350-1250 mz 
were followed by 60 MS/MS scans in the mass range of 100-1500 Da (total cycle time 3.302 s). 
Switching criteria were set to ions greater than mass to charge ratio (m/z) 350 and smaller than 1250 
(m/z) with charge state 2-5 and an abundance threshold of more than 120 counts. Former target ions 
were excluded for 12 s. IDA rolling collision energy (CE) parameters script was used for 
automatically controlling CE. SWATH quantification analysis parameters were the same as for 
SWATH ID, with the following exceptions: cycle time 3.332 s and MS parameters set to 15 Da 
windows with 1 Da overlap between mass range 350-1250 Da followed by 40 MS/MS scans in the 
mass range of 350-1250 Da. SWATH analysis method has been published in Nättinen et al 2018. 2 
 
Immunoblotting 
17 Og of protein from retinal lysates was loaded and run into 4-12% gradient gel (NuPAGE; 
Invitrogen, Carlsbad, CA, USA) and transferred on polyvinylidene fluoride membranes (Amersham 
Biosciences, Little Chalfont, UK). Membranes were blocked with 5 % NFM/TBST and specific 
proteins were detected by immunoblotting with following primary antibodies: rabbit anti-Flna 
(Cat#ab76289, Abcam, Cambridge, UK),  rabbit anti-Myh (Cat#11128-1-AP, Proteintech, Rosemont, 
IL, USA), and goat anti-GAPDH (Cat#ab9483, Abcam) followed by appropriate HRP-coupled 
secondary antibodies. Clarity Western ECL Substrates (Bio-Rad, Hercules, CA, USA) were used for 
enhanced chemiluminescence and Western blot images were captured via ImageQuant LAS 4000 
software (ImageQuant; GE Healthcare, Chalfont St. Giles, UK). Proteins levels for Myh9, total Flna 
and FlnaCT were quantified by densitometry using Adobe Photoshop CS3 software, and GAPDH was 
used to normalize for protein loading. A calibration protein samples was included in every membrane 
to enable combined results from several membranes. Two sample t-test was used to analyze 
differences between the relative protein expression levels of control and OIR retinas. 
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Supplementary Figure 1. Graphs illustrating the expression of crystallins during OIR. Retinas 
were harvested from OIR and control retinas at P13, P17 and P42 and samples were analyzed by MS-
SWATH proteomics. The means with standard error bars are shown for control (red) and OIR (blue) 
samples for crystallins, which were most upregulated group of proteins at P13 OIR compared to room 
air controls. Asterisks identifies statistically significant differences between the two groups before P 
value adjustement (P value <0.05).  SURWHLQTXDQWLILFDWLRQ based on only one specific peptide. 
 
Supplementary Figure 2. Differentially expressed proteins in OIR. Mice pups were exposed to 
hyperoxia-induced OIR, and retinas were harvested at P13, P17 and P42. All retina samples were 
analyzed by MS-SWATH and the data underwent statistical analysis to compare control and OIR 
samples in each time point. The means and standard error bars are shown for control (red) and OIR 
(blue) samples for some of the proteins during hypoxia at P13 (A) and at the peak of 
neovascularization at P17 (B). Asterisks identifies statistically significant differences between the 
two groups before P value adjustment (*), and after P value (**) adjustment. Note that some of the 
differently expressed proteins were illustrated in Figure 5. 
 

Supplementary Figure 3. Illustration from canonical pathway analysis from Ingenuity 
Pathway Analysis (IPA) showing phototransduction pathway with proteins downregulated in 
OIR retinas (colored) compared to controls at P13. 


Supplementary Figure 4. Proteins involved in neurotransmission remained at reduced level at 
P42 OIR. (A) IPA analysis at P42 revealed decreased neurotransmission at P42 OIR compared to 
controls. Protein expression levels of neurotransmission proteins during OIR are visualized. Asterisks 
identifies statistically significant differences between the two groups before P value adjustement (P 
value <0.05). (B) KEGG pathway analysis revealed that some of these proteins (red star) are part of 
synaptic vesicle cycle. 
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